assay_id,assay_type,description,method,bao_preferred_term,bao_id
1870082,B,Agonist activity at GAL4 DNA binding domain fused glucocorticoid receptor ligand binding domain (unknown origin) at 0.25 to 25 uM by FRET-based assay,FRET-based assay,fluorescence resonance energy transfer,BAO_0000001
1991217,B,Agonist activity at human FXR expressed in human HuH7 cells by luciferase reporter gene assay relative to control,luciferase reporter gene assay,luciferase reporter gene assay,BAO_0002661
2168604,B,Antagonist activity at ERbeta (unknown origin) assessed as inhibition of fluorescein-labelled coactivator PGC1 peptide recruitment at 34 nM incubated for 30 mins by LanthaScreen TR-FRET assay relative to control,LanthaScreen TR-FRET assay,time resolved fluorescence resonance energy transfer,BAO_0000004
643730,B,Antagonist activity at mouse cloned Smo receptor expressed in NIH-3T3 cells co expressing Gli1 binding site after 15 hrs by luciferase reporter gene assay,luciferase reporter gene assay,luciferase reporter gene assay,BAO_0002661
835167,B,Inhibition of FGFR2 by TR-FRET analysis,TR-FRET analysis,time resolved fluorescence resonance energy transfer,BAO_0000004
985206,B,Inhibition of His-thrombin-TEV-tagged cIAP1 BIR3 domain (260 to 352) (unknown origin) after 1 hr by TR-FRET assay,TR-FRET assay,time resolved fluorescence resonance energy transfer,BAO_0000004
1743583,B,Inhibition of human EPHB1 (565 to 984 residues) assessed as residual activity at 500 nM in presence of 33P-ATP by filter binding assay relative to control,filter binding assay,filter assay,BAO_0000401
1565425,B,Inhibition of human His-tagged BRD4 bromodomain 2 expressed in Escherichia coli BL21(DE3)-R3-pRARE2 cells by FRET assay,FRET assay,fluorescence resonance energy transfer,BAO_0000001
700796,B,Inhibition of human MAPKAP-K3 at 10 uM after 60 mins by TR-FRET assay,TR-FRET assay,time resolved fluorescence resonance energy transfer,BAO_0000004
744077,B,Inhibition of MAPK14 at 25 uM by TR-FRET assay,TR-FRET assay,time resolved fluorescence resonance energy transfer,BAO_0000004
811334,B,Inhibition of N-terminal 6-histine tagged Bacillus anthracis LF 263-C terminal catalytic domain using MCA-KKVYPYPME-Dap(Dnp)-NH2 as substrate after 4 hrs by FRET analysis,FRET analysis,fluorescence resonance energy transfer,BAO_0000001
2254352,B,Inhibition of N-terminal thioredoxin-His6 tagged human BCL6 BTB domain (5 to 129 residues) expressed in Escherichia coli BL21-AI incubated for 2 hrs by TR-FRET assay,TR-FRET assay,time resolved fluorescence resonance energy transfer,BAO_0000004
701191,B,Inhibition of p110alpha/p85alpha at 10 uM after 60 mins by TR-FRET assay,TR-FRET assay,time resolved fluorescence resonance energy transfer,BAO_0000004
839971,B,Inhibition of PI3K alpha by continuous TR-FRET assay,continuous TR-FRET assay,time resolved fluorescence resonance energy transfer,BAO_0000004
812850,B,Inhibition of PI3K p110alpha E545K mutant using [gamma33P]ATP by filter binding assay,filter binding assay,filter assay,BAO_0000401
1774531,B,Inhibition of recombinant GST-tagged human PDE9A2 expressed in insect cells using cGMP as substrate after 1 hr by IMAP TR-FRET assay,IMAP TR-FRET assay,IMAP Assay of phosphoproteins (Molecular Devices),BAO_0140036
1869472,B,Inhibition of recombinant human LSD1 (172 to 852 residues) using biotin-labelled H3K4me2 (1 to 24 residues) after 1 hr by TR-FRET assay,TR-FRET assay,time resolved fluorescence resonance energy transfer,BAO_0000004
1463128,B,Intrinsic activity at GAL4 tagged human PPARalpha ligand binding domain expressed in HEK293 cells at 1 uM by luciferase reporter gene assay relative to 1 uM GW2331,luciferase reporter gene assay,luciferase reporter gene assay,BAO_0002661
2123220,B,Positive allosteric modulator activity in mouse kappa opioid receptor stably expressed in HEK293 cell membrane assessed as binding affinity of dyn A1-13 to orthosteric binding site at 0.1 uM coincubated with dyn A1-13 for 90 mins by radioligand competition binding assay,,,
877387,B,Transactivation of GAL4-fused human PPARdelta ligand binding domain transfected in african green monkey COS7 cells by luciferase reporter gene assay,luciferase reporter gene assay,luciferase reporter gene assay,BAO_0002661
1672555,B,Competitive inhibition of human mTOR using 4EBP1 as substrate in presence of [33gammaP]-ATP after 120 mins by filter binding method,filter binding method,filter assay,BAO_0000401
1699332,B,Inhibition of human MSK1 assessed as residual activity at 1 uM in presence of 33P-ATP by filter-binding assay relative to control,filter-binding assay,filter assay,BAO_0000401
518848,B,Inhibition of PDGFRbeta by Ambit binding assay,Ambit binding assay,KINOMEScan assay,BAO_0003011
1870247,B,Binding affinity to ABL2 in SILAC-labeled human MDA-MB-231 cells lysate by mass spectrometry based kinAffinity assay,mass spectrometry based kinAffinity assay,mass spectrometry,BAO_0000055
1708876,B,Binding affinity to AURKB in human NCI-H358 cells at 1 uM by mass spectrometry based pull down assay,mass spectrometry based pull down assay,affinity selection,BAO_0002501
1708876,B,Binding affinity to AURKB in human NCI-H358 cells at 1 uM by mass spectrometry based pull down assay,mass spectrometry based pull down assay,mass spectrometry,BAO_0000055
1992205,B,Binding affinity to BLM in human HCT116 cells cotransfected with DSB model and I-SceI plasmid assessed as reduction in recruitment of protein to DSB site in DNA at 1 uM measured after 24 hrs by chromatin immunoprecipitation assay,chromatin immunoprecipitation assay,immunoprecipitation,BAO_0002508
2163697,B,Binding affinity to FGFR4 (unknown origin) assessed as dissociation constant by competition binding assay,,,
1500556,B,Binding affinity to FLAG-6His-Tev-ATAD2 (950 to 1148) Y1021A/N1064A double mutant (unknown origin) expressed in Escherichia coli BL21 (DE3) by SPR analysis,SPR analysis,surface plasmon resonance,BAO_0000054
651193,B,Binding affinity to GGTase-1 F52Y/Y126T mutant assessed as prenylation of RhoA GTPase by Western blot method,Western blot method,western blot,BAO_0002424
2149103,B,Binding affinity to Grb2-SH2 domain (unknown origin) by ELISA,ELISA,ELISA,BAO_0000134
1708761,B,Binding affinity to HAX1 in human NCI-H358 cells at 1 uM by mass spectrometry based pull down assay,mass spectrometry based pull down assay,affinity selection,BAO_0002501
1708761,B,Binding affinity to HAX1 in human NCI-H358 cells at 1 uM by mass spectrometry based pull down assay,mass spectrometry based pull down assay,mass spectrometry,BAO_0000055
2248318,B,Binding affinity to His6-fused BRD3 BD2 (unknown origin) assessed as change in melting temperature at 100 uM incubated for 30 mins by thermal shift assay,thermal shift assay,thermal shift assessment method,BAO_0040024
1588202,B,Binding affinity to His6-tagged human recombinant SMARCA2B bromodomain expressed in Escherichia coli BL21(DE3)-R3-pRARE2 cells by VP-ITC microcalorimetry,VP-ITC microcalorimetry,VP-ITC Isothermal Titration Calorimeter,BAO_0000708
2069197,B,Binding affinity to HPGDS (unknown origin) assessed as change in melting temperature by thermal shift assay,thermal shift assay,thermal shift assessment method,BAO_0040024
887349,B,Binding affinity to human cyclophilin A by fluorescence polarization assay,fluorescence polarization assay,fluorescence polarization,BAO_0000003
2090202,B,Binding affinity to human full length N-terminal GST-tagged HDAC4 by surface plasmon resonance analysis,surface plasmon resonance analysis,surface plasmon resonance,BAO_0000054
1724121,B,Binding affinity to human GABAA receptor alpha1beta3gamma2 expressed in HEK293 TetR cells assessed as photolabeling at 0.7 uM after 30 mins in presence of 300 uM GABA by coomassie blue staining based fluorographic method,coomassie blue staining based fluorographic method,Coomassie dye protein staining,BAO_0002464
1802989,B,Binding affinity to human His-tagged MOF by SPR analysis,SPR analysis,surface plasmon resonance,BAO_0000054
2122060,B,Binding affinity to human MAP3K2 at 1 uM by KINOMEscan scanMAX assay relative to control,KINOMEscan scanMAX assay,KINOMEScan assay,BAO_0003011
1701466,B,Binding affinity to human N-terminal MDMx (1 to 134 residues) expressed in Escherichia coli BL21 (DE3) after 15 mins in presence of 5-FAM-LTFEHYWAQLTS by FP assay,FP assay,fluorescence polarization,BAO_0000003
1792441,B,Binding affinity to human partial length KIT V559D/V654A double mutant (Y545 to D952 residues) expressed in bacterial expression system assessed as remaining unbound target protein level at 1000 nM by Kinomescan method relative to control,Kinomescan method,KINOMEScan assay,BAO_0003011
1874045,B,Binding affinity to human partial length PIK3CA E545A mutant (R108 to N1068 residues) expressed in mammalian expression system measured after 1 hr by kinomescan method,kinomescan method,KINOMEScan assay,BAO_0003011
1277119,B,Binding affinity to human recombinant TLR4 at >320 uM by SPR method,SPR method,surface plasmon resonance,BAO_0000054
1502837,B,Binding affinity to KAT2A in human HUT78 cells incubated for 45 mins by mass spectrometry based bromosphere chemoproteomic assay,mass spectrometry based bromosphere chemoproteomic assay,mass spectrometry,BAO_0000055
1708895,B,Binding affinity to MAP2K2 in human NCI-H358 cells at 1 uM by mass spectrometry based pull down assay,mass spectrometry based pull down assay,affinity selection,BAO_0002501
1708895,B,Binding affinity to MAP2K2 in human NCI-H358 cells at 1 uM by mass spectrometry based pull down assay,mass spectrometry based pull down assay,mass spectrometry,BAO_0000055
798461,B,Binding affinity to N-terminus biotinylated human Hsp90 alpha by surface plasmon resonance assay,surface plasmon resonance assay,surface plasmon resonance,BAO_0000054
1329392,B,Binding affinity to NR4A1 (unknown origin) at 0.1 uM by luciferase reporter gene assay relative to control,luciferase reporter gene assay,luciferase reporter gene assay,BAO_0002661
1475233,B,Binding affinity to RPA70N protein (unknown origin) by HSQC NMR-based titration method,HSQC NMR-based titration method,nuclear magnetic resonance,BAO_0000160
1475233,B,Binding affinity to RPA70N protein (unknown origin) by HSQC NMR-based titration method,HSQC NMR-based titration method,titration method,BAO_0002413
1880975,B,Binding affinity to wild-type human full length DRAK2 (M1 to C372 residues) expressed in bacterial expression system assessed as residual binding level at 1 uM by Kinomescan method relative to control,Kinomescan method,KINOMEScan assay,BAO_0003011
1741239,B,Binding affinity to wild-type human full length DYRK2 (M1 to S528 residues) expressed in mammalian expression system assessed as residual binding at 1 uM by Kinomescan method relative to control,Kinomescan method,KINOMEScan assay,BAO_0003011
1857117,B,Binding affinity to wild-type human full length DYRK2 (M1 to S528 residues) expressed in mammalian expression system assessed as residual binding level at 1 uM by Kinomescan method relative to control,Kinomescan method,KINOMEScan assay,BAO_0003011
1773707,B,Binding affinity to wild-type human full length ERK2 (M1 to S360 residues) expressed in bacterial expression system assessed as residual binding level at 1 uM by Kinomescan method relative to control,Kinomescan method,KINOMEScan assay,BAO_0003011
1857182,B,Binding affinity to wild-type human full length GRK3 (M1 to L688 residues) expressed in mammalian expression system assessed as residual binding level at 1 uM by Kinomescan method relative to control,Kinomescan method,KINOMEScan assay,BAO_0003011
1773879,B,Binding affinity to wild-type human full length PHKG1 (M1 to Y387 residues) expressed in bacterial expression system assessed as residual binding level at 1 uM by Kinomescan method relative to control,Kinomescan method,KINOMEScan assay,BAO_0003011
1889839,B,Binding affinity to wild-type human full length SRPK1 (M1 to S655 residues) expressed in bacterial expression system assessed as residual binding level at 10 uM by Kinomescan method relative to control,Kinomescan method,KINOMEScan assay,BAO_0003011
1881035,B,Binding affinity to wild-type human partial length autoinhibited FLT3 (H564 to Y969 residues) expressed in mammalian expression system assessed as residual binding level at 1 uM by Kinomescan method relative to control,Kinomescan method,KINOMEScan assay,BAO_0003011
1750933,B,Binding affinity to wild-type human partial length BMPR1A (Q214 to I532 residues) expressed in Escherichia coli BL21 at 1 uM by Kinomescan method relative to control,Kinomescan method,KINOMEScan assay,BAO_0003011
1889510,B,Binding affinity to wild-type human partial length CHEK1 (M1 to G289 residues) expressed in bacterial expression system assessed as residual binding level at 10 uM by Kinomescan method relative to control,Kinomescan method,KINOMEScan assay,BAO_0003011
1889540,B,Binding affinity to wild-type human partial length DMPK2 (S46 to S408 residues) expressed in bacterial expression system assessed as residual binding level at 10 uM by Kinomescan method relative to control,Kinomescan method,KINOMEScan assay,BAO_0003011
1833370,B,Binding affinity to wild-type human partial length EPHA3 (D604 to K889 residues) expressed in bacterial expression system assessed as residual binding level at 1 uM by Kinomescan method relative to control,Kinomescan method,KINOMEScan assay,BAO_0003011
1833461,B,Binding affinity to wild-type human partial length LYN (C219 to Q511 residues) expressed in bacterial expression system assessed as residual binding level at 1 uM by Kinomescan method relative to control,Kinomescan method,KINOMEScan assay,BAO_0003011
1792617,B,Binding affinity to wild-type human partial length N-terminal RSK4 kinase domain 1 (M1 to E397 residues) expressed in mammalian expression system assessed as remaining unbound target protein level at 1000 nM by Kinomescan method relative to control,Kinomescan method,KINOMEScan assay,BAO_0003011
1751186,B,Binding affinity to wild-type human partial length NEK9 (P32 to R328 residues) expressed in Escherichia coli BL21 at 1 uM by Kinomescan method relative to control,Kinomescan method,KINOMEScan assay,BAO_0003011
1805757,B,Binding affinity to wild-type human partial length PDGFRA (V575 to D1002 residues) expressed in mammalian expression system assessed as enzyme remaining activity at 1 uM by Kinomescan assay relative to control,Kinomescan assay,KINOMEScan assay,BAO_0003011
1792559,B,Binding affinity to wild-type human partial length PIKFYVE (F1512 to C2098 residues) expressed in mammalian expression system assessed as remaining unbound target protein level at 1000 nM by Kinomescan method relative to control,Kinomescan method,KINOMEScan assay,BAO_0003011
1741481,B,Binding affinity to wild-type human partial length PRKCI (H215 to V587 residues) expressed in mammalian expression system assessed as residual binding at 1 uM by Kinomescan method relative to control,Kinomescan method,KINOMEScan assay,BAO_0003011
1889827,B,Binding affinity to wild-type human partial length SBK1 (P23 to P348 residues) expressed in mammalian expression system assessed as residual binding level at 10 uM by Kinomescan method relative to control,Kinomescan method,KINOMEScan assay,BAO_0003011
1774008,B,Binding affinity to wild-type human partial length ULK2 (M1 to S301 residues) expressed in mammalian expression system assessed as residual binding level at 1 uM by Kinomescan method relative to control,Kinomescan method,KINOMEScan assay,BAO_0003011
1708497,B,Binding affinity to YWHAQ in human NCI-H23 cells at 1 uM by mass spectrometry based pull down assay,mass spectrometry based pull down assay,affinity selection,BAO_0002501
1708497,B,Binding affinity to YWHAQ in human NCI-H23 cells at 1 uM by mass spectrometry based pull down assay,mass spectrometry based pull down assay,mass spectrometry,BAO_0000055
1923667,B,Binding affinity to zanamivir/oseltamivir resistant recombinant Influenza A virus (A/Moscow/10/99(H3N2)) Neuraminidase N2 E119V/I222L double mutant expressed in baculovirus infected insect cells assessed as dissociation rate constant measured up to 400 sec by surface plasmon resonance analysis,surface plasmon resonance analysis,surface plasmon resonance,BAO_0000054
1908752,B,Covalent binding affinity to human GRK5 assessed as covalent bond formation with Cys474 by intact protein mass spectrometry,intact protein mass spectrometry,mass spectrometry,BAO_0000055
1555070,B,"Displacement of 5-(Dimethylamino)-2-(6-((5-(4-(4-methylpiperidin-1-yl)butyl)-5,6,7,8-tetrahydronaphthalen-2-yl)oxy)hexyl)isoindoline-1,3-dione from sigma 1 receptor (unknown origin) expressed in MCF7 after 75 mins by flow cytometry",flow cytometry,flow cytometry,BAO_0000005
1844861,B,Displacement of 6N-FAM from SF1 LBD (218 to 461 residues) (unknown origin) expressed in Escherichia coli BL21 pLysS by competitive binding based fluorescence polarization assay,fluorescence polarization assay,fluorescence polarization,BAO_0000003
1707368,B,Displacement of biotinylated histone H3K14 peptide ligand from human recombinant His-tagged BRD4 bromodomain-1 measured after 10 mins by TR-FRET assay,TR-FRET assay,time resolved fluorescence resonance energy transfer,BAO_0000004
1582085,B,Displacement of biotinylated ligand from recombinant His-tagged EP300 (unknown origin) incubated for 10 mins by TR-FRET assay,TR-FRET assay,time resolved fluorescence resonance energy transfer,BAO_0000004
572761,B,Displacement of F-BakBH3 from Bfl-1 by fluorescence polarization assay,fluorescence polarization assay,fluorescence polarization,BAO_0000003
1767769,B,Displacement of FAM-labeled HIF-1alpha peptide from VBC (unknown origin) by fluorescence polarization assay,fluorescence polarization assay,fluorescence polarization,BAO_0000003
2074786,B,Displacement of FITC-WFYpSPFLE from human Pin1 (45-163) catalytic domain by fluorescence polarization assay,fluorescence polarization assay,fluorescence polarization,BAO_0000003
1464501,B,Displacement of S6c from rat ETB receptor after 1 hr by Lowry method,Lowry method,Lowry assay,BAO_0002465
1578808,B,Inhibition of human SRPK3 (41 to 567 amino acid residues) expressed in bacterial system assessed as enzyme activity at 10 uM by KINOMEScan assay,KINOMEScan assay,KINOMEScan assay,BAO_0003011
1634426,B,Stabilization of BRAF in human K562 cells after 1 hr by thermal shift assay,thermal shift assay,thermal shift assessment method,BAO_0040024
159810,B,Apparent binding constant was determined by ethidium displacement assay in poly (dG-dC),ethidium displacement assay,ethidium bromide DNA staining,BAO_0002474
1929784,B,Binding affinity to calf thymus duplex DNA assessed as induction of ellipticity at 25 to 200 uM in pH 8.9 phosphate buffer by circular dichroism method,circular dichroism method,circular dichroism,BAO_0000161
745305,B,Binding affinity to human telomeric (5'-FAM-GGG TTA GGG TTA GGG TTA GGG-TAMRA-3') DNA assessed as concentration required to cause half maximal change in melting temperature by FRET-melting assay (Rvb = 59.4 degC),FRET-melting assay,fluorescence resonance energy transfer,BAO_0000001
1983677,B,Binding affinity to SOX2 promoter 5'-CTTTGTT-3' DNA in mouse Hepa1 cells assessed as reduction in SOX2 mRNA expression incubated for 48 hrs by qRT-PCR analysis,qRT-PCR analysis,quantitative PCR,BAO_0003031
2125288,B,Binding affinity to telomeric Htg24 G-quadruplex DNA G17A mutant (unknown origin) assessed as negative fluorescence signal at 5 uM under pH condition 7.4 by fluorescence titration analysis,fluorescence titration analysis,fluorescence method,BAO_0000046
2125288,B,Binding affinity to telomeric Htg24 G-quadruplex DNA G17A mutant (unknown origin) assessed as negative fluorescence signal at 5 uM under pH condition 7.4 by fluorescence titration analysis,fluorescence titration analysis,titration method,BAO_0002413
802309,B,Binding affinity at 5-HT2A receptor by radioligand displacement assay,,,
1278477,B,Binding affinity to human 5-HT3A receptor W90C mutant after 24 hrs by liquid scintillation counting analysis,liquid scintillation counting analysis,scintillation counting,BAO_0000405
966209,B,Binding affinity to human adenosine A1 receptor by radioligand displacement assay,,,
963174,B,Binding affinity to human dopamine D1 receptor by radioligand binding assay,,,
964384,B,Binding affinity to human MC4 receptor at 10 uM by radioligand displacement assay relative to control,,,
1632014,B,Binding affinity to rat M2 receptor by radio-ligand binding assay,,,
1673874,B,"Displacement of [125I]-[Nle75, Tyr77] Pyr1-apelin-13 from YFP-tagged human APJ receptor expressed in HEK293 cell membranes after 1 hr by gamma-counting method",gamma-counting method,scintillation counting,BAO_0000405
1996342,B,Displacement of [125I]-NDP-alpha-MSH from human MC4R expressed in CHO-K1 cell membranes incubated for 3 hrs by top-count beta counting relative to control,top-count beta counting,scintillation counting,BAO_0000405
1737421,B,Displacement of [125I]CCK-8s from human recombinant CCK1 receptor at 10 uM after 60 mins by scintillation counting analysis relative to control,scintillation counting analysis,scintillation counting,BAO_0000405
559547,B,"Displacement of [3H] 2-((1R,2R,5R)-5-hydroxy-2-(3-hydroxypropyl)cyclohexyl)-5-(2-methyloctan-2-yl)phenol from human CB2 receptor expressed CHO-K1 cells by liquid scintillation counting",liquid scintillation counting,scintillation counting,BAO_0000405
2085047,B,"Displacement of [3H]-(S)-2-(6-((2',6'-dimethyl-4'-(3-(methylsulfonyl)propoxy)biphenyl-3-yl)methoxy)-2,3-dihydrobenzofuran-3-yl)acetic acid from human recombinant full-length GPR40 expressed in human HEK293 cell membrane assessed as Koff rate measured after 2 hrs by radioligand competitive assay",,,
775804,B,Displacement of [3H]-epibatidine from alpha1betagammadelta nAChR in human TE671 cellular membranes at 5 uM after 2 hrs by liquid scintillation counting,liquid scintillation counting,scintillation counting,BAO_0000405
1757987,B,Displacement of [3H]-GR65630 from human 5-HT3 receptor expressed in HEKT cells after 90 mins by microbeta scintillation counting analysis,microbeta scintillation counting analysis,scintillation counting,BAO_0000405
1329184,B,Displacement of [3H]-pentazocine from human recombinant sigma-1 receptor expressed in CHO cells after 180 mins by beta counting analysis,beta counting analysis,scintillation counting,BAO_0000405
2132583,B,Displacement of [3H]-SCH23390 from D3 receptor (unknown origin) expressed in HEK293T cell membranes measured after 2 hrs by microbeta scintillation counting method,microbeta scintillation counting method,scintillation counting,BAO_0000405
638891,B,Displacement of [3H](+)-pentazocine from sigma1 opioid receptor from guinea pig brain cortex at 1 uM after 150 mins by scintillation counting,scintillation counting,scintillation counting,BAO_0000405
1864044,B,Displacement of [3H]4-DAMP from recombinant human M3 receptor after 60 mins by scintillation counting analysis,scintillation counting analysis,scintillation counting,BAO_0000405
1711349,B,Displacement of [3H]BRL 43694 from human recombinant 5-HT3 receptor at 10 uM after 120 mins by scintillation counting analysis relative to control,scintillation counting analysis,scintillation counting,BAO_0000405
969677,B,Displacement of [3H]Citalopram from SERT in Sprague-Dawley rat brain homogenate after 60 mins by scintillation counting analysis,scintillation counting analysis,scintillation counting,BAO_0000405
1881838,B,Displacement of [3H]CP 55940 from human recombinant CB1 receptor at 10 uM after 120 mins by scintillation counting analysis relative to control,scintillation counting analysis,scintillation counting,BAO_0000405
1565155,B,Displacement of [3H]CP55940 from CB1 receptor in Wistar rat brain incubated for 60 mins by radioactive filter binding assay,radioactive filter binding assay,filter assay,BAO_0000401
2074736,B,Displacement of [3H]CP55940 from human CB1R transfected in HEK293EBNA cell membranes incubated for 90 mins by Microbeta TriLux based luminescence analysis,Microbeta TriLux based luminescence analysis,MicroBeta TriLux,BAO_0003094
2074736,B,Displacement of [3H]CP55940 from human CB1R transfected in HEK293EBNA cell membranes incubated for 90 mins by Microbeta TriLux based luminescence analysis,Microbeta TriLux based luminescence analysis,luminescence method,BAO_0000045
1930260,B,Displacement of [3H]diprenorphine from rat delta opioid receptor expressed in rat C6 cell membranes measured after 1 hr by liquid scintillation counting method,liquid scintillation counting method,scintillation counting,BAO_0000405
976681,B,Displacement of [3H]DPCPX from human adenosine A1 receptor expressed in CHO cells up to 0.1 mM after 2 hrs by scintillation counting analysis,scintillation counting analysis,scintillation counting,BAO_0000405
2068291,B,Displacement of [3H]DTG from sigma 2 receptor in rat PC12 cells incubated for 120 mins in presence of [3H]-(+)-pentazocine by liquid scintillation counting method,liquid scintillation counting method,scintillation counting,BAO_0000405
764674,B,Displacement of [3H]Iloprost from human prostanoid IP receptor expressed in CHO cells after 60 mins by liquid scintillation counting,liquid scintillation counting,scintillation counting,BAO_0000405
642096,B,Displacement of [3H]methylspiperone from human cloned 5HT2A receptor expressed in HEK293 cells at 1 uM after 90 mins by liquid scintillation counting,liquid scintillation counting,scintillation counting,BAO_0000405
1724104,B,Displacement of [3H]muscimol from human GABAA receptor alpha1beta3gamma2 expressed in HEK293 TetR cell membranes after 1 hr by liquid scintillation counting method,liquid scintillation counting method,scintillation counting,BAO_0000405
687324,B,Displacement of [3H]ZM241385 from human adenosine A2B receptor transfected in CHO cells after 60 mins by scintillation counting,scintillation counting,scintillation counting,BAO_0000405
3703,B,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 7 receptor; ND means not determined,,,
2228192,B,Inhibition of human full length NSD2 at 10 uM by radioisotope-based filter binding assay,radioisotope-based filter binding assay,filter assay,BAO_0000401
751198,B,Inhibition of human recombinant NTS1 receptor at 10 uM by radioligand binding assay,,,
788137,B,Inhibition of human recombinant RON at 0.5 uM by radiometric filter-binding assay,radiometric filter-binding assay,filter assay,BAO_0000401
1568614,B,Agonist activity at rat mGlu2 receptor by FRET based mGlu sensor assay,FRET based mGlu sensor assay,fluorescence resonance energy transfer,BAO_0000001
1432679,B,Inhibition of integrin alphavbeta3 (unknown origin) by Merck binding assay,,,
1921767,B,"Inhibition of MAGL in human U937 cell homogenates incubated for 5 mins in presence of [1,2,3-3H]2-OG by liquid scintillation spectroscopy",liquid scintillation spectroscopy,scintillation counting,BAO_0000405
536900,B,Binding affinity to bone assessed as drug level bound to cattle bone meal powder by fluorescence assay,fluorescence assay,fluorescence method,BAO_0000046
602453,B,Binding affinity to human ALK at 200 nM by cell-based competition binding assay relative to control in presence of DTT,,,
1979354,B,Binding affinity to human partial length BRDT bromodomain 1 (N21 to E137 residues) expressed in bacterial expression system by BROMOscan assay,BROMOscan assay,,
1851040,B,Binding affinity to human partial length TRIM33 (D882 to A1087 residues) expressed in bacterial expression system at 1 uM by BROMOscan assay,BROMOscan assay,,
2209071,B,Binding affinity to human recombinant ERbeta by competitive fluorometric binding assay,competitive fluorometric binding assay,fluorescence method,BAO_0000046
2262115,B,Binding affinity to human Sirt3 (118 to 399 residues) assessed as dissociation constant (Koff) of ternary complex using acetylated MnSOD peptide as substrate in presence of OAADPr by short DNA nano levers based switchSENSE microfluid bio-chip analysis,short DNA nano levers based switchSENSE microfluid bio-chip analysis,,
1329746,B,Binding affinity to M4 receptor (unknown origin) by PDSP assay,,,
989636,B,Binding affinity to N-terminal domain of human Hsp90alpha by FAXS competitive binding assay,FAXS competitive binding assay,,
2231580,B,Binding affinity to PRDX6 in human MDA-MB-453 cells at 10 uM measured after 6 hrs in presence of 100 uM PES by pull-down assay,pull-down assay,affinity selection,BAO_0002501
215016,B,Binding affinity towards rat kidney Vasopressin V2 receptor by using functional assay,,,
1329505,B,"Competitive binding affinity to GLO-1 in HEK293T cell lysate at 50 uM after overnight incubation followed by UV-irradiation for 1 hr by pull-down assay in presence of N-(4-(4-(5-fluoro-4-(2-(methylsulfonamido)phenylamino)pyrimidin-2-ylamino)benzoyl)phenyl)-5-((3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)pentanamide",pull-down assay,affinity selection,BAO_0002501
2235893,B,Covalent binding affinity to N-terminal His-Smt-tagged MSK1 C-terminal kinase domain (414 to 738 residues) (unknown origin) expressed in Escherichia coli BL21 (DE3) at 1:1 ratio of enzyme to compound measured after 3 hrs by LC-MS analysis relative to control,LC-MS analysis,mass spectrometry,BAO_0000055
1751447,B,Displacement of TNP-ATP from recombinant Salmonella typhimurium GST-tagged DHp-catalytic domain PhoQ (332 to 487 residues) expressed in Escherichia coli XA90 aafter 10 mins by fluorescence assay,fluorescence assay,fluorescence method,BAO_0000046
2059816,B,"Inhibition of 5-(3-((1r,4r)-4-((5S,8S,11S,14S,17S,20S,29S)-11-((1H-imidazol-4-yl)methyl)-1,33-diamino-5-carbamoyl-17-(4-(4-(4-((4-(dimethylamino)phenyl)diazenyl)phenyl)butanamido)butyl)-8,14-bis(3-guanidinopropyl)-20-methyl-7,10,13,16,19,22,25,28-octaoxo-6,9,12,15,18,21,24,27-octaazatritriacontan-29-ylcarbamoyl)cyclohexyl)thioureido)-2-(6-hydroxy-3-oxo-3H-xanthen-9-yl)benzoic acid binding to SIRT2 (unknown origin) measured after 2 hrs in presence of NAD+ by fluorometric method",fluorometric method,fluorescence method,BAO_0000046
1899144,B,Inhibition of CMFDA binding to human N-terminal 6x-His-tagged GSTO1-1 at 10 uM preincubated for 30 mins followed by CMFDA addition and measured after 30 mins in presence of 10 uM MnCl2 by in-gel fluorescence binding assay,in-gel fluorescence binding assay,fluorescence method,BAO_0000046
2017246,B,Inhibition of FITC-labeled palmitate tracer binding to N-terminal His6-tagged human TEAD4 (217 to 434 residues) expressed in Escherichia coli BL21-CodonPlus (DE3)-RIPL cells assessed as ratio of Kinact to Ki measured after 1 to 24 hrs by fluorescence assay,fluorescence assay,fluorescence method,BAO_0000046
815855,B,Inhibition of GPIbalpha-vWF binding assessed as inhibition of ristocetin-induced platelet agglutination at 100 uM after 2 mins by static agglutination assay,static agglutination assay,,
653926,B,Binding affinity to (CAG-CAG) trinucleotide repeats at 120 uM by ESI-TOF mass spectroscopy,ESI-TOF mass spectroscopy,mass spectrometry,BAO_0000055
695627,B,Binding affinity to CGT ACA GTG DNA sequence assessed as change in melting temperature by thermal denaturation assay,thermal denaturation assay,nucleic acid conformation assessment,BAO_0000469
1770851,B,Binding affinity to Staphylococcus aureus genomic DNA at pH 7.4 at 294 K by fluorescence quenching analysis,fluorescence quenching analysis,fluorescence method,BAO_0000046
516355,B,Displacement of [3H]estradiol from human recombinant estrogen receptor alpha by radiometric assay relative to estradiol,,,
1650979,B,Displacement of [3H]NVP-QAW039 from human DP2 receptor expressed in CHO cell membranes assessed as association rate constant by TopCount scintillation assay,TopCount scintillation assay,scintillation counting,BAO_0000405
474423,B,Displacement of [3H]R5020 from human PR in human T47D cells by whole cell assay,,,
1460139,B,Displacement of [3H]spiperone from human D4.4 receptor stably expressed in CHO cell membranes by competitive binding assay,,,
560038,B,Agonist activity at human CB1 receptor expressed in SF9 cells assessed as inhibition of CP-55940-stimulated GTP binding,,,
2208413,B,Antagonist activity at AMPA receptor (unknown origin),,,
1698440,B,Antagonist activity at muscarinic M1 receptor (unknown origin),,,
67359,B,Functional ERalpha receptor activity in transcriptional activation assay in MCF-7 cells,transcriptional activation assay,targeted transcriptional assay,BAO_0010044
1275686,B,Inhibition of LYN (unknown origin) after 90 mins by TR-FRET/IMAP fluorescence polarization assay,TR-FRET/IMAP fluorescence polarization assay,IMAP Assay of phosphoproteins (Molecular Devices),BAO_0140036
1746638,B,Inhibition of recombinant human full length N-terminal His6-tagged and N-terminal GST-tagged CDK5/p35 expressed in baculovirus Sf21 insect cells at 10 uM by filter binding radioactive ATP transferase assay relative to control,filter binding radioactive ATP transferase assay,transferase activity assay,BAO_0002795
1746638,B,Inhibition of recombinant human full length N-terminal His6-tagged and N-terminal GST-tagged CDK5/p35 expressed in baculovirus Sf21 insect cells at 10 uM by filter binding radioactive ATP transferase assay relative to control,filter binding radioactive ATP transferase assay,filter assay,BAO_0000401
1746680,B,Inhibition of recombinant human N-terminal/C-terminal His6-tagged PAK2 (3 to end residues) expressed in Escherichia coli at 10 uM by filter binding radioactive ATP transferase assay relative to control,filter binding radioactive ATP transferase assay,transferase activity assay,BAO_0002795
1746680,B,Inhibition of recombinant human N-terminal/C-terminal His6-tagged PAK2 (3 to end residues) expressed in Escherichia coli at 10 uM by filter binding radioactive ATP transferase assay relative to control,filter binding radioactive ATP transferase assay,filter assay,BAO_0000401
60971,B,pKi value for Dopamine receptor D2 binding site,,,
2164646,B,"Reactivation of NIMP-inhibited recombinant His-TEV-tagged human AChE expressed in CHO-K1 cells assessed as reactivation constant, Kr by measuring thiophenol levels by UV-vis absorption spectroscopy",UV-vis absorption spectroscopy,absorbance,BAO_0000070
1636438,B,"Potency index, ratio of galantamine IC50 to compound IC50 for horse serum BuChE",,,
229363,B,Ratio of cytochrome P450 19A1 Ki for 6-alpha substituted steroid relative to 6-beta substitution,,,
656702,B,Ratio of IC50 for inhibition of HIV1 HXB2 gp120-mediated viral infusion into HEK293 cells in presence of 45 mg/ml human serum albumin to IC50 for inhibition of HIV1 HXB2 gp120-mediated viral infusion into HEK293 cells in absence of 45 mg/ml human serum albumin,,,
490012,B,Ratio of Kcat to Km for HIV1 reverse transcriptase assessed as nucleotide excision activity in presence of 0.5 uM dCTP,,,
1674696,B,Ratio of Kinact to Ki for S-adenosyl-L-homocysteine hydrolase (unknown origin),,,
86691,B,Ratio of Kreact to that of Kinact was determined on human leukocyte elastase(HLE),,,
941525,B,Ratio of TXA IC50 to compound IC50 for human Glu-plasminogen/fibrinogen interaction by clot-lysis buffer assay,clot-lysis buffer assay,,
55304,B,Selective index for Dihydrofolate reductase was determined by IC50(rat liver) / IC50(Toxoplasma gondii),,,
229570,B,Selectivity as ratio of pA2 value against alpha-2 receptor to that of alpha-1 receptor.,,,
146271,B,Selectivity ratio is IC50 value of mu-opioid receptor to that of delta-opioid receptor,,,
1895739,B,Selectivity ratio of ki for muscarinic M4 receptor (unknown origin) expressed in CHO cells to muscarinic M2 receptor (unknown origin) expressed in CHO cells,,,
37378,B,Evaluated for its agonist activity and the binding affinity against human Beta-1 adrenergic receptor in membranes from chinese hamster ovary cell,,,
157538,B,Binding affinity against HIV-Protease was determined,,,
303054,B,Binding affinity against Synechocystis strain PCC6803 DXP reductoisomerase,,,
305518,B,Binding affinity for Prostaglandin G/H synthase 2 (COX-2),,,
63532,B,Binding affinity measured in CHO cells stably transfected with the human endothelin B receptor,,,
963022,B,Binding affinity to 5HT2A receptor (unknown origin),,,
1279931,B,Binding affinity to AT1 receptor (unknown origin),,,
476688,B,Binding affinity to CB2 receptor,,,
2197346,B,Binding affinity to D4 receptor (unknown origin) assessed as dissociation constant,,,
2051018,B,Binding affinity to DAT (unknown origin) assessed as inhibition of ligand binding at 10 uM relative to control,,,
440187,B,Binding affinity to GAPDH in human erythrocytes,,,
1921222,B,Binding affinity to HIV1 cYTA48P envelope glycoprotein gp120 infected in human TZM-b1 cells assessed as induction of conformational changes by measuring combination index at 450:1 ratio of test compound to KD-247 measured after 48 hrs,,,
1576400,B,Binding affinity to HIV1 protease N88D mutant,,,
447281,B,Binding affinity to human ERalpha,,,
448621,B,Binding affinity to human ERbeta,,,
445591,B,Binding affinity to human ERbeta,,,
537086,B,Binding affinity to human KHS1,,,
2197502,B,Binding affinity to human recombinant 5-HT2A assessed as inhibition constant,,,
818809,B,Binding affinity to human recombinant 5HT2C receptor,,,
658554,B,Binding affinity to human recombinant GABAA receptor,,,
2130535,B,Binding affinity to human SIRT1 human MDA-MB-231 cells assessed as increase in thermal stability heated for 3 mins up to 1 degC at 10 uM by cellular thermal shift assay,cellular thermal shift assay,thermal shift assay,BAO_0010261
944109,B,Binding affinity to JAK1 (unknown origin) at 10 uM relative to control,,,
1829544,B,Binding affinity to LSD1 (unknown origin),,,
877015,B,Binding affinity to mGlu1 receptor in rat brain pons at 7.4 MBq after 60 mins by autoradiography,autoradiography,autoradiography,BAO_0002527
877019,B,Binding affinity to mGlu1 receptor in rat thalamus at 7.4 MBq after 60 mins by autoradiography,autoradiography,autoradiography,BAO_0002527
532315,B,Binding affinity to Plasmodium falciparum spermidine synthase by saturation transfer difference-NMR experiment,saturation transfer difference-NMR experiment,nuclear magnetic resonance,BAO_0000160
627749,B,Binding affinity to PPARgamma,,,
981821,B,Binding affinity to PPARgamma (unknown origin) at 10 uM by Polarscreen competitor assay relative to rosiglitazone,Polarscreen competitor assay,PolarScreen Competitor Assay Kit,BAO_0003076
2260017,B,Binding affinity to TCP-stimulated NMDA (unknown origin),,,
33373,B,Binding affinity towards Alpha-2B adrenergic receptor; ND=No data,,,
33326,B,Binding affinity towards human alpha-2 adrenergic receptor,,,
154359,B,Binding affinity towards peroxisome proliferator activated receptor gamma (PPAR gamma); weakly active,,,
774448,B,Binding constant for DRAK1 kinase domain,,,
774208,B,Binding constant for NIM1 kinase domain,,,
302265,B,Binding potency towards Delta opioid receptor of mouse vas deferens,,,
140186,B,Compound was evaluated for its binding affinity towards M2 receptor in rat brainstem,,,
223059,B,Compound was evaluated for the binding constant for association with nicotinic acetylcholine receptor (nAChR),,,
562670,B,Displacement of 4-methylumbelliferydiacetyl-chitobiose from Serratia marcescens ChiB,,,
36274,B,Displacement of DHT from human androgen receptor,,,
195972,B,In vitro binding affinity for human renin at pH 7.2,,,
514923,B,Inhibition of luciferin binding site of Photuris pennsylvanica luciferase by competitive KinaseGlo Plus Max luminescent assay,competitive KinaseGlo Plus Max luminescent assay,Kinase-Glo Plus Luminescent Kinase Assay,BAO_0000678
66845,B,Relative binding affinity (RBA) for estrogen receptor at 0C,,,
31220,B,Saturation binding of human Adenosine A2A receptor (H250N) at pH 6.8,,,
1460861,B,"Ratio of Kd for GST-tagged phosphorylated p38-alpha (unknown origin) to IC50 for uman recombinant 5'-c-myc, His6-tagged p38-alpha using MK2 (46-400) as substrate",,,
52456,B,"Ability to interact with DNA was assessed by a DNA/ethidium bromide dye displacement assay, expressed as DC50 for polydAdT",ethidium bromide dye displacement assay,ethidium bromide DNA staining,BAO_0002474
2052717,B,Binding affinity at Escherichia coli pBR322 DNA assessed as unwinding of supercoiled DNA at 10 uM incubated for 10 mins in presence of human topoisomerase 1 by agarose gel based electrophoresis,agarose gel based electrophoresis,agarose gel,BAO_0010020
494280,B,Binding affinity to calf thymus DNA assessed as circular dichrosim at 10 uM,circular dichrosim,circular dichroism,BAO_0000161
815840,B,Binding affinity to calf thymus DNA assessed as melting temperature,,,
2260695,B,Binding affinity to calf thymus DNA assessed as stabilization by measuring melting temperature at ratio of 0.2 by UV/vis spectrophotometric (Rvb = 66 degreeC),UV/vis spectrophotometric,absorbance,BAO_0000070
434771,B,Binding affinity to calf thymus double stranded DNA,,,
1929767,B,Binding affinity to calf thymus duplex DNA assessed as induction of hyperchromic shift at 257 nanometer at 50 uM in pH 7 phosphate buffer by UV-vis spectrophotometric analysis,UV-vis spectrophotometric analysis,absorbance,BAO_0000070
2105425,B,Binding affinity to DNA Hoxa9-binding site-5'-ATTTA/5'ATGA double mutant (strand a-CTGCGTAGCGTCACGACCGC/strand b-GCGGTCGTGACGCTACGCAG) (unknown origin) by UV/visible spectrophotometric method,UV/visible spectrophotometric method,absorbance,BAO_0000070
588548,B,Binding affinity to Escherichia coli pUC19 DNA assessed as form 1 DNA level at 0.130 mM after 8.08 hrs by agarose gel electrophoresis,agarose gel electrophoresis,agarose gel,BAO_0010020
1925887,B,Binding affinity to pre-annealed c-MYC G-quadruplex (unknown origin) in 10 mM Tris.HCl buffer containing 100 mM KCl at pH 7.4 by UV/Visible spectroscopy,UV/Visible spectroscopy,absorbance,BAO_0000070
52280,B,Binding constant for DNA by ethidium bromide displacement,ethidium bromide displacement,ethidium bromide DNA staining,BAO_0002474
52441,B,Compound was evaluated for DNA-binding affinity using poly[d(GC)]2,,,
49482,B,The ability to reversibly bind to DNA using ethidium bromide displacement assay was reported as apparanet DNA binding constant for Coliphage T4 DNA,ethidium bromide displacement assay,ethidium bromide DNA staining,BAO_0002474
2131421,B,Inhibition of C-terminal 6-His-tagged beta-catenin (1 to 781 residues) (unknown origin) expressed in Escherichia coli BL21 (DE3)-N-terminal biotinylated human BCL9 (350 to 375 residues) protein-protein interaction incubated for 1 hr by Alphascreen assay,Alphascreen assay,alphascreen,BAO_0000130
146904,B,Binding affinity against Opioid receptor delta 1 of rat brain using [3H]-nor BNI as radioligand.,,,
60370,B,Binding affinity determined by measuring its ability to displace [3H]N-0437 radioligand in CHO-K1 cells on Cloned Human Dopamine receptor D2,,,
139241,B,Binding affinity towards cloned human muscarinic acetylcholine receptor M4 stably expressed in CHO-K1 cells using [3H]N-methylscopolamine,,,
304048,B,Binding affinity towards human 5-hydroxytryptamine receptor 6 expressed in HeLa cells using the radioligand [3H]LSD,,,
303088,B,Binding affinity towards human D2 short receptor using [3H]spiperone expressed in CHO cells,,,
154707,B,Binding affinity was measured as selectivity for sigma-1 site over phencyclidine (PCP) receptor in rat using [3H]TCP as radioligand at 10 uM,,,
148551,B,"Compound was evaluated for Inhibition of binding of [3H]- DAMGO at Rat brain mu receptor binding site, Expt-2",,,
3306,B,Compound was evaluated for the binding affinity against human cloned 5-hydroxytryptamine 4 receptor in HeLa cells using [3H]-LSD as the radioligand,,,
149007,B,Compound was tested for binding affinity towards Opioid receptor mu 1 by displacing [3H]DAGO radioligand in rat brain P2 synaptosomes membranes.,,,
30534,B,Concentration required for 50% inhibition of [3H]NECA binding on rat brain adenosine A2 receptor,,,
143180,B,Concentration required to inhibit opiate receptor using radioligand [3H]- Etorphine,,,
143997,B,Concentration that inhibited 50% of binding of 125 I -PYY ligand to human Neuropeptide Y receptor type 5,,,
31060,B,"Displacement [3H]-CGS-21,680 from Adenosine A2A receptor in rat striatal membrane.",,,
1842749,B,Displacement of (+)-[3H]pentazocine from sigma1 receptor in guinea pig brain membranes,,,
47961,B,Displacement of [125I]- BH-CCK-8 from Cholecystokinin type B receptor of guinea pig cortex,,,
686801,B,Displacement of [125I]-C5a Anaphylatoxin from anaphylatoxin C5a at 1 to 3 uM,,,
327286,B,"Displacement of [125I]-His5, D-Tyr6]GnRH from mutant GnRHR, GnRHR S186D",,,
1559495,B,Displacement of [125I]Endothelin-1 from human recombinant Endothelin-B receptor expressed in CHO cells at 10'-5 M,,,
1285619,B,Displacement of [125I]Sarile from human AT2 receptor expressed in HEK293 cells,,,
161303,B,Displacement of [3H]- PDBu from Protein kinase C gamma C1b domain,,,
855538,B,Displacement of [3H]-5-CT from human 5-HT7b receptor expressed in HEK293 cells after 1 hr,,,
2027,B,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,,,
1545083,B,Displacement of [3H]-ketanserin from human 5-HT2A receptor expressed in HEK293 cells incubated for 1 hr,,,
2079764,B,Displacement of [3H]-LSD from human 5HT6 receptor expressed in HEK293 cell membrane at 10^-6 M measured after 60 mins relative to control,,,
793560,B,Displacement of [3H]-PGE2 from mouse EP4 receptor expressed in CHO cells after 60 mins by liquid scintillation counter,liquid scintillation counter,scintillation counting,BAO_0000405
31960,B,Displacement of [3H]-SCH- 58261 from human adenosine A2A receptor expressed in CHO cells; range 65-92,,,
965434,B,Displacement of [3H]8-OH-DPAT from human recombinant 5HT1A receptor expressed in CHOK1 cells after 60 mins,,,
602018,B,Displacement of [3H]AMPA from wild type rat GluR2 S1S2 ligand binding core,,,
746775,B,Displacement of [3H]AVP from human V2 receptor expressed in CHO cells,,,
852592,B,Displacement of [3H]CCPA from adenosine A1 receptor in rat brain cortical membrane,,,
860849,B,Displacement of [3H]epibatidine from rat alpha2beta4 nACHR at 10 uM,,,
466333,B,Displacement of [3H]estradiol from human recombinant ERbeta relative to estradiol,,,
68591,B,Displacement of [3H]GABA from rat brain Gamma-aminobutyric acid receptor,,,
795795,B,Displacement of [3H]histamine from rat H1R,,,
435199,B,Displacement of [3H]MK-801 from rat brain NMDA receptor,,,
509571,B,Displacement of [3H]MRS1754 from human adenosine A2B receptor expressed in CHO cell membrane,,,
990753,B,Displacement of [3H]N-alpha-methylhistamine from rhesus monkey histamine H3 receptor expressed in CHO cells,,,
538318,B,Displacement of [3H]NECA from human cloned adenosine A3 receptor expressed in human HeLa cells,,,
525851,B,Displacement of [3H]NMS from human cloned muscarinic M5 receptor expressed in insect Sf9 cells,,,
449795,B,Displacement of [3H]oxytocin from human oxytocin receptor expressed in CHO cells at 1000 nM,,,
160631,B,Displacement of [3H]PDBu from protein kinase C beta C1b domain,,,
157813,B,Displacement of [3H]PGE-2 from human Prostaglandin E receptor EP3 expressed in CHO-KI cells,,,
1514952,B,Displacement of [3H]raclopride from dopamine D2 receptor in Sprague-Dawley rat striatal membranes after 30 mins,,,
493450,B,Displacement of [3H]Ro-154513 from benzodiazepine binding site of GABAA alpha-4-beta-2-gamma-2 receptor expressed in HEK293T cells,,,
748964,B,Displacement of [3H]SCH233930 from human D1 receptor expressed in HEK cells,,,
588130,B,Displacement of [3H]spiperone from human cloned dopamine D3 expressed in CHO cells,,,
1703545,B,Displacement of [3H]spiperone from human D2-short receptor expressed in CHO cell membranes,,,
665576,B,Displacement of [3H]Spiperone from human dopamine D2 short receptor expressed in CHO cells,,,
431066,B,Displacement of [3H]SR141716A from human CB1 receptor expressed in CHO cells at 10 uM,,,
597913,B,Displacement of [3H]SR141716A from rat brain CB1 receptor,,,
938376,B,"Displacement of [3H]WIN-55,212-2 from human recombinant CB2 receptor expressed in CHO-K1 cells at 10 uM relative to control",,,
535635,B,Displacement of 2-[125I]iodomelatonin from human MT1 receptor expressed in HEK293 cells,,,
428740,B,Displacement of 3H]RX821002 from rat cortex adrenergic alpha-2 receptor,,,
512423,B,Displacement of radioligand from adrenergic alpha2A receptor,,,
2161850,B,Displacement of sphingosine D-erythro [3-3H] I- phosphate from human S1P2 receptor expressed in CHO cell membrane,,,
320918,B,In vitro binding affinity towards cloned human 5-HT6 receptor using [3H]5-carboximidotryptamine as radioligand: nd=Not determined,,,
60815,B,In vitro for its ability to displace [3H]- spiperone from cloned human Dopamine receptor D4 expressed in CHO cells,,,
306826,B,In vitro inhibitory concentration against binding of the [3H]glycine to strychnine-insensitive glycine binding sites of rat N-methyl-D-aspartate glutamate receptor,,,
2430,B,Inhibition constant for in vitro inhibition of [3H]ketanserin binding to rat frontal cortex membranes 5-hydroxytryptamine 2A receptor,,,
868,B,"Inhibition of [3H]8-hydroxy-2-dipropylamino-1,2,3,4-tetrahydronaphthalene binding to 5-hydroxytryptamine 1A receptor in hippocampus region of rat brain; Residual radioligand binding higher than 50%",,,
320862,B,Inhibition of [3H]CGS-21680 binding to adenosine A2a receptor of human striatal membrane,,,
196770,B,Inhibition of 3[H]9-cis-retinoic acid binding to Retinoic acid receptor RXR-alpha expressed in CV-1 cells,,,
145392,B,Inhibition of binding of [3H]diprenorphine to cloned human Opioid receptor kappa 1 expressed in CHO cell membrane,,,
149058,B,Inhibition of binding of [3H]oxytocin to rat uterine oxytocin receptor,,,
1457920,B,Inhibition of human 5HT3 at 10 uM by [3H]RL43694 binding assay relative to control,,,
592537,B,Inhibition of radioligand binding to human adrenergic Alpha-2C receptor at 10 uM after 60 mins,,,
876212,B,Inhibition of radioligand binding to human adrenergic alpha2c receptor at 10 uM,,,
28218,B,Percent remaining of radioligand [3H]DPCPX binding to human adenosine A1 receptor at 10 uM,,,
325472,B,Percentage inhibition of [3H]NECA binding to cloned human adenosine A2A receptor expressed in CHO cells at 10 uM,,,
1845612,B,"Potency index, ratio of [Nle15]MG11 IC50 to test compound IC50 for displacement of [177Lu] PP-F11N from CCK2R (unknown origin) transfected in A431 cells incubated for 1 hr at 4 degree C followed by compound washout with PBS buffer using Lu3+ labeled compound by Cobra-2 gamma counter method",Cobra-2 gamma counter method,scintillation counting,BAO_0000405
1991288,B,Ratio of Ki for displacement of [3H]DPCPX from Sprague-Dawley rat whole brain membrane A1AR in presence of GTP to Ki for displacement of [3H]DPCPX from Sprague-Dawley rat whole brain A1AR,,,
143173,B,"Tested for displacement of radioligand [3H]naloxone from opiate receptor; ND, no data",,,
140142,B,The compound was tested for binding affinity against muscarinic acetylcholine receptor using QNB as radioligand,,,
210907,B,The compound was tested for relative binding affinity against calf uterine receptor using [3H]estradiol as radioligand,,,
146556,B,The compound was tested for the ability to displace mu-receptor specific radioligand [3H]DAGO,,,
147295,B,"Ability to stimulate binding to delta-opioid receptor using GTP-gamma -S-binding assay in guinea pig caudate membranes, blocked with 20 nM naltrindole (NTI); NS= no stimulation",GTP-gamma -S-binding assay,,
1987633,F,Anti-urolithic activity in synthetic urine assessed as decrease in absorbance at 10 mg/mL relative to control,,,
1730151,F,Antagonist activity at CCR10 in human MDA-MB-231 cells assessed as inhibition of CCL27-induced proliferation up to 10 uM preincubated for 2 hrs followed by CCL27 addition measured after 48 hrs by MTT assay,MTT assay,MTT reduction assay,BAO_0002457
1525752,F,Agonist activity at dopamine D4 receptor (unknown origin) expressed in CHO cells assessed as calcium mobilization at 3 uM,,,
820807,F,Agonist activity at human S1P3 receptor expressed in CHO cells coexpressing Gq/i5 G-protein assessed as Ca2+ mobilization after 60 to 90 mins by FLIPR assay relative to 1-(4-(6-benzylbenzofuran-2-yl)-3-fluorobenzyl)azetidine-3-carboxylic acid,FLIPR assay,FLIPR Membrane Potential Assay Kit,BAO_0003088
790543,F,Inhibition of basal activity of human histamine H3 receptor expressed in CHO cells assessed as inhibition of RAHM-induced [35S]GTPgammaS binding after 4 hrs by beta liquid scintillation counting,beta liquid scintillation counting,scintillation counting,BAO_0000405
642034,F,Agonist activity at human C3a receptor in human U937 cells assessed as induction of intracellular calcium release,,,
649008,F,Agonist activity at muscarinic M4 receptor in wild type mouse hippocampal CA1 pyramidal neuron assessed as increase in carbachol-induced reduction in excitatory postsynaptic current at 5 uM by whole-cell electrophysiology relative to control,whole-cell electrophysiology,electrophysiological method,BAO_0000424
1839334,F,Modulation of M2 polarization in mouse RAW264.7 cells assessed as up regulation of PPARGC1A mRNA expression at 300 nM measured after 24 hrs by qRT-PCR analysis,qRT-PCR analysis,quantitative reverse transcription PCR,BAO_0002090
2232845,F,Antibacterial activity against methicillin-resistant Staphylococcus aureus assessed as bacterial growth inhibition incubated for 5 hrs under shaking condition by resazurin dye based assay,resazurin dye based assay,resazurin reduction assay,BAO_0002459
2146152,F,Antibacterial activity against Acinetobacter baumannii ATCC 17961 assessed as inhibition of bacterial growth after 16 hrs by two fold dilution method,two fold dilution method,dilution method,BAO_0002418
1836348,F,Antibacterial activity against carbapenem-resistant Escherichia coli BAA-2469 clinical isolates after 18 to 20 hrs in aerobic condition by CLSI-based broth microdilution assay,CLSI-based broth microdilution assay,dilution method,BAO_0002418
1799294,F,Bactericidal activity against methicillin-sensitive Pseudomonas aeruginosa PAO1 at 400 uM after 18 hrs by resazurin-dye based fluorescence assay,resazurin-dye based fluorescence assay,resazurin reduction assay,BAO_0002459
1795430,F,Antibacterial activity against Arcobacter butzleri after 17 hrs by NCCLS broth microdilution method,NCCLS broth microdilution method,dilution method,BAO_0002418
1690980,F,Antibacterial activity against Escherichia coli MTCC 443 after 24 hrs by broth microdilution method,broth microdilution method,dilution method,BAO_0002418
1679715,F,Antibacterial activity against Bacillus subtilis NBRC 13719 after overnight incubation by microdilution method,microdilution method,dilution method,BAO_0002418
1564255,F,Antibacterial activity against Pseudomonas aeruginosa PAO1 clinical isolate assessed as inhibition of biofilm formation at 4 ug/ml after 18 to 22 hrs by crystal violet staining-based polystyrene microtiter plate reader method in presence of 0.5 ug/ml colistin,crystal violet staining-based polystyrene microtiter plate reader method,crystal violet staining,BAO_0002468
1525254,F,Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC 43300 after 18 to 24 hrs by spectrophotometric analysis,spectrophotometric analysis,spectrophotometry method,BAO_0000049
1438531,F,Antibacterial activity against erythromycin-susceptible Staphylococcus aureus by agar microdilution method,agar microdilution method,dilution method,BAO_0002418
948159,F,"Antibacterial activity against methicillin-susceptible, MLS-resistant (inducible) Staphylococcus epidermidis E1 by broth microdilution method",broth microdilution method,dilution method,BAO_0002418
936279,F,Bactericidal activity against Salmonella typhi after 72 hrs by serial subcultivation method,serial subcultivation method,dilution method,BAO_0002418
790861,F,Antibacterial activity against erythromycin-sensitive Staphylococcus aureus ATCC 13709 by broth microdilution method,broth microdilution method,dilution method,BAO_0002418
724668,F,Antibacterial activity against 1 x 10'4 CFU Streptococcus pneumoniae ATCC 6305 after 18 hrs by CLSI 2-fold agar dilution method,CLSI 2-fold agar dilution method,dilution method,BAO_0002418
695454,F,Antibacterial activity against Salmonella enterica serovar Enteritidis assessed as percent susceptible isolates by broth microdilution method,broth microdilution method,dilution method,BAO_0002418
526824,F,Antibacterial activity against Staphylococcus epidermidis NCIMB 8853 by microdilution method,microdilution method,dilution method,BAO_0002418
1477470,F,Antimicrobial activity against Bacillus subtilis ATCC 6633 after 24 hrs by twofold dilution method,twofold dilution method,dilution method,BAO_0002418
1461117,F,Antimicrobial activity against Bacillus subtilis ATCC 6633 assessed as inhibition of microbial growth incubated for 24 hrs by broth dilution method,broth dilution method,dilution method,BAO_0002418
735749,F,Antibacterial activity against Salmonella by broth macrodilution method,broth macrodilution method,dilution method,BAO_0002418
719615,F,Antimicrobial activity against Enterococcus faecalis ATCC 29212 by broth microdilution method,broth microdilution method,dilution method,BAO_0002418
691129,F,Antimicrobial activity against Staphylococcus epidermidis C960 by broth microdilution method,broth microdilution method,dilution method,BAO_0002418
2214320,F,Antibiofilm activity against vancomycin-intermediate Staphylococcus aureus ATCC 700699 assessed as inhibition of biofilm formation incubated for 24 hrs by crystal violet staining based assay,crystal violet staining based assay,crystal violet staining,BAO_0002468
645376,F,"Antimicrobial activity against Beta-lactamase-negative, ampicillin-resistant Haemophilus influenzae with Ile449Val, Asn526Lys substitutions in penicillin-binding protein 3 by broth microdilution method",broth microdilution method,dilution method,BAO_0002418
1731240,F,Antifungal activity against Candida albicans ATCC 90028 assessed as inhibition of metabolic activity at 10 ug/ml after 48 hrs in presence of 80 ug/ml fluconazol by XTT assay relative to control,XTT assay,XTT reduction assay,BAO_0002458
916663,F,Antifungal activity against Rhizoctonia solani SRRC 1443 assessed as thin hyphae at 20 uM after 48 hr by microscopic analysis,microscopic analysis,microscopy,BAO_0002526
848248,F,Antifungal activity against Aspergillus fumigatus ATCC 26934 by NCCLS broth microdilution method,NCCLS broth microdilution method,dilution method,BAO_0002418
801636,F,Antifungal activity against Penicillium funiculosum ATCC 36839 treated for 72 hrs followed by sub-cultivated for 5 days by serial dilution method,serial dilution method,dilution method,BAO_0002418
522532,F,Antifungal activity against Candida tropicalis isolate 0022-021 after 24 hrs by CLSI M27-A2 broth microdilution method in presence of RPMI 1640 medium,CLSI M27-A2 broth microdilution method,dilution method,BAO_0002418
732024,F,Antimicrobial activity against 5-fluorocytosine resistant Candida glabrata isolate TE34-78 harboring Fcr1 L136R mutant assessed as lowest concentration inhibiting growth >=80% by broth microdilution method,broth microdilution method,dilution method,BAO_0002418
990003,F,Trypanocidal activity against bloodstream forms of Trypanosoma brucei brucei Lister 427 clone 221a after 72 hrs by AlamarBlue assay,AlamarBlue assay,alamarBlue,BAO_0100002
978205,F,Trypanocidal activity against epimastigote stage of Trypanosoma cruzi Y at 5 ug/mL after 72 hrs by MTT assay relative to control,MTT assay,MTT reduction assay,BAO_0002457
672622,F,Antiplasmodial activity against Plasmodium falciparum D10 ATCC 563 after 72 hrs by SYBR green assay,SYBR green assay,SYBR Green I DNA staining,BAO_0002473
2064349,F,Antiviral activity against HCV J6/JFH/JC1 harboring D168V mutant infected in human Huh7.5 cells assessed as inhibition of viral replication measured after 72 hrs by qRT-PCR analysis,qRT-PCR analysis,quantitative reverse transcription PCR,BAO_0002090
1930399,F,Antiviral activity against wild-type HIV1 NL4-3 infected infected in human MT2 cells assessed as reduction in extracellular RNA at 1 uM and measured after 30 hrs post infection by Alu-LTR PCR protocol based method,Alu-LTR PCR protocol based method,real-time PCR ,BAO_0002084
1478223,F,Antiviral activity against Hepatitis C virus genotype 1b Con 1 infected in human HuH7 cells at 40 nM after 72 hrs by luciferase assay in presence of 24 nM simeprevir,luciferase assay,luciferase reporter gene assay,BAO_0002661
725903,F,Antiviral activity against Hepatitis C virus subtype 1b expressing NS3 R155K mutant infected in HuH7 cells after 48 hrs by by luciferase reporter assay,luciferase reporter assay,luciferase reporter gene assay,BAO_0002661
671559,F,Antiviral activity against Influenza A virus (A/Hong Kong/1073/99(H9N2)) infected in MDCK cells assessed as log reduction in viral titer at 960 uM after 48 hrs by MTT assay,MTT assay,MTT reduction assay,BAO_0002457
894707,F,Induction of ultrastructure damage of root tip statocytes in Zea mays (maize) seedlings assessed as reduction in organelle size at 400 ug/L measured 48 hr post dose by transmission electron microscopy,transmission electron microscopy,transmission electron microscopy,BAO_0000455
475911,F,Effect on Phorbol 12-myristate 13-acetate-induced macropinocytosis in mouse J774 macrophage cells at 20 uM by video microscopy,video microscopy,microscopy,BAO_0002526
2054653,F,Induction of ROS-mediated apoptosis in human SGC-7901 cells assessed as early apoptotic cells at 1 uM incubated for 48 hrs by annexin V-PE and 7-AAD staining based flow cytometry analysis (Rvb = 1.89 %),annexin V-PE and 7-AAD staining based flow cytometry analysis,flow cytometry,BAO_0000005
2054653,F,Induction of ROS-mediated apoptosis in human SGC-7901 cells assessed as early apoptotic cells at 1 uM incubated for 48 hrs by annexin V-PE and 7-AAD staining based flow cytometry analysis (Rvb = 1.89 %),annexin V-PE and 7-AAD staining based flow cytometry analysis,Annexin V apoptosis assay,BAO_0010265
2029444,F,Induction of autophagy in human DLD-1 cells assessed as vacuole formation at 7.5 uM incubated for 24 hrs in presence of Bafilomycin-A1 by phase contrast microscopic analysis,phase contrast microscopic analysis,phase contrast microscopy,BAO_0000458
1868563,F,Induction of morphological changes in human HeLa cells assessed as swollen cells at IC50 after 24 hrs by phase contrast microscopic analysis,phase contrast microscopic analysis,phase contrast microscopy,BAO_0000458
1853595,F,Induction of cell cycle arrest in human HCT116 cells assessed as debris content at 0.7 uM incubated for 24 hrs by PI staining based flow cytometric analysis (Rvb = 0%),PI staining based flow cytometric analysis,propidium iodide DNA staining,BAO_0002476
1853595,F,Induction of cell cycle arrest in human HCT116 cells assessed as debris content at 0.7 uM incubated for 24 hrs by PI staining based flow cytometric analysis (Rvb = 0%),PI staining based flow cytometric analysis,flow cytometry,BAO_0000005
2105132,F,Induction of cell cycle arrest in human MDA-MB-231 cells assessed as accumulation at S phase at 4 uM incubated for 24 hrs by PI staining based flow cytometry analysis (Rvb = 40.37 to 57.89 %),PI staining based flow cytometry analysis,propidium iodide DNA staining,BAO_0002476
2105132,F,Induction of cell cycle arrest in human MDA-MB-231 cells assessed as accumulation at S phase at 4 uM incubated for 24 hrs by PI staining based flow cytometry analysis (Rvb = 40.37 to 57.89 %),PI staining based flow cytometry analysis,flow cytometry,BAO_0000005
2023321,F,Antiproliferative activity against human HUT78 assessed as reduction in cell viability incubated for 3 days by Cell Titer Blue assay,Cell Titer Blue assay,CellTiter-Blue Cell Viability Assay (Promega),BAO_0140012
1846866,F,Antiproliferative activity against human HL7702 cells assessed as reduction in cell viability after 48 hrs by MTT assay,MTT assay,MTT reduction assay,BAO_0002457
1721442,F,Antiproliferative activity against human NCI-H2228 cells harboring EML4-ALK after 72 hrs by MTT assay,MTT assay,MTT reduction assay,BAO_0002457
2214047,F,Antiproliferative activity against human A498 cells assessed as cell growth inhibition measured after 72 hrs by SRB assay,SRB assay,sulforhodamine B staining,BAO_0002460
2108689,F,Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay,MTT assay,MTT reduction assay,BAO_0002457
989337,F,Antiproliferative activity against human HCT8 cells by MTT assay,MTT assay,MTT reduction assay,BAO_0002457
641661,F,Growth inhibition of human HL-60(TB) cells after 48 hrs by sulforhodamine B assay,sulforhodamine B assay,sulforhodamine B staining,BAO_0002460
623020,F,Growth inhibition of human HCC2998 cells at 100 nM after 96 hrs by MTT assay,MTT assay,MTT reduction assay,BAO_0002457
1831311,F,"Induction of multi-nuclei formation in mouse LL/2 cells at 0.8 uM after 24 hrs in presence of paclitaxel by 4',6-diamidino-2-phenylindole staining-based assay","4',6-diamidino-2-phenylindole staining-based assay",colorimetric cell staining method,BAO_0002455
1789168,F,Induction of apoptosis in human MDA-MB-231 cells assessed as early apoptotic cells at 10 uM after 72 hrs by annexin-V/propidium iodide double staining based flow cytometry (Rvb = 0.02%),annexin-V/propidium iodide double staining based flow cytometry,propidium iodide DNA staining,BAO_0002476
1789168,F,Induction of apoptosis in human MDA-MB-231 cells assessed as early apoptotic cells at 10 uM after 72 hrs by annexin-V/propidium iodide double staining based flow cytometry (Rvb = 0.02%),annexin-V/propidium iodide double staining based flow cytometry,flow cytometry,BAO_0000005
1789168,F,Induction of apoptosis in human MDA-MB-231 cells assessed as early apoptotic cells at 10 uM after 72 hrs by annexin-V/propidium iodide double staining based flow cytometry (Rvb = 0.02%),annexin-V/propidium iodide double staining based flow cytometry,Annexin V apoptosis assay,BAO_0010265
1727619,F,Induction of apoptosis in human HCC827 cells assessed as increase in hypodiploid DNA content at 50 to 100 nM after 72 hrs by propidium iodide staining flow cytometry,propidium iodide staining flow cytometry,propidium iodide DNA staining,BAO_0002476
1727619,F,Induction of apoptosis in human HCC827 cells assessed as increase in hypodiploid DNA content at 50 to 100 nM after 72 hrs by propidium iodide staining flow cytometry,propidium iodide staining flow cytometry,flow cytometry,BAO_0000005
1717246,F,Induction of apoptosis in human MGC803 cells assessed as late apoptotic cells at 8 uM after 48 hrs Annexin V-FITC/propidium iodide based flow cytometry (1%),Annexin V-FITC/propidium iodide based flow cytometry,propidium iodide DNA staining,BAO_0002476
1717246,F,Induction of apoptosis in human MGC803 cells assessed as late apoptotic cells at 8 uM after 48 hrs Annexin V-FITC/propidium iodide based flow cytometry (1%),Annexin V-FITC/propidium iodide based flow cytometry,flow cytometry,BAO_0000005
1717246,F,Induction of apoptosis in human MGC803 cells assessed as late apoptotic cells at 8 uM after 48 hrs Annexin V-FITC/propidium iodide based flow cytometry (1%),Annexin V-FITC/propidium iodide based flow cytometry,Annexin V apoptosis assay,BAO_0010265
1656536,F,Growth inhibition of human LOXIMVI cells incubated for 48 hrs by sulforhodamine B assay,sulforhodamine B assay,sulforhodamine B staining,BAO_0002460
1647420,F,Growth inhibition of human KM12 cells assessed as cell growth at 0.003 uM incubated for 48 hrs by sulforhodamine B assay relative to control,sulforhodamine B assay,sulforhodamine B staining,BAO_0002460
1647301,F,Growth inhibition of human HCC2998 cells assessed as cell growth at 5 uM incubated for 48 hrs by sulforhodamine B assay relative to control,sulforhodamine B assay,sulforhodamine B staining,BAO_0002460
1580193,F,Potentiation of 2.5 nM (-)-lomaiviticin A-induced cytotoxicity against human K562 cells assessed as combination index at 10 uM after 48 hrs by cell titer-glo luminescence assay,cell titer-glo luminescence assay,CellTiter-Glo Luminescent Cell Viability Assay,BAO_0000682
1561734,F,Induction of apoptosis in human K562 cells assessed as up-regulation of Bax protein expression by Western blot analysis,Western blot analysis,western blot,BAO_0002424
1561733,F,Induction of apoptosis in human K562 cells assessed as downregulation of Bcl-2 protein expression by Western blot analysis,Western blot analysis,western blot,BAO_0002424
1516953,F,Induction of apoptosis in human MGC803 cells assessed as compact and condensed chromatin at 10 uM after 48 hrs using Hoechst 33258 staining by fluorescence microscopic analysis,Hoechst 33258 staining by fluorescence microscopic analysis,Hoechst,BAO_0000116
1516953,F,Induction of apoptosis in human MGC803 cells assessed as compact and condensed chromatin at 10 uM after 48 hrs using Hoechst 33258 staining by fluorescence microscopic analysis,Hoechst 33258 staining by fluorescence microscopic analysis,fluorescence microscopy,BAO_0000450
1472216,F,Induction of apoptosis in human HepG2 cells assessed as viable cells at 20 uM after 6 hrs by annexin V/propidium iodide staining-based flow cytometric analysis (Rvb = 90.9%),annexin V/propidium iodide staining-based flow cytometric analysis,propidium iodide DNA staining,BAO_0002476
1472216,F,Induction of apoptosis in human HepG2 cells assessed as viable cells at 20 uM after 6 hrs by annexin V/propidium iodide staining-based flow cytometric analysis (Rvb = 90.9%),annexin V/propidium iodide staining-based flow cytometric analysis,flow cytometry,BAO_0000005
1472216,F,Induction of apoptosis in human HepG2 cells assessed as viable cells at 20 uM after 6 hrs by annexin V/propidium iodide staining-based flow cytometric analysis (Rvb = 90.9%),annexin V/propidium iodide staining-based flow cytometric analysis,Annexin V apoptosis assay,BAO_0010265
1462240,F,Cell cycle arrest in human MCF7 cells assessed as accumulation at G0 phase at 2 uM after 48 hrs by FACS analysis (Rvb = 1.83 +/- 0.28%),FACS analysis,flow cytometry,BAO_0000005
1455786,F,Stimulation of growth in human MCF7 cells at 0.1 to 20 uM after 4 days by MTT assay,MTT assay,MTT reduction assay,BAO_0002457
1349583,F,Induction of apoptosis in p53 knock down human HCT116 cells assessed as PARP cleavage at 1 uM after 24 hrs by immunoblotting analysis,immunoblotting analysis,immunoassay,BAO_0000129
1339546,F,Induction of apoptosis in human A549 cells assessed as necrotic cells at 5 uM after 48 hrs by annexin V/PI staining-based FACS analysis (Rvb = 2.8 %),annexin V/PI staining-based FACS analysis,propidium iodide DNA staining,BAO_0002476
1339546,F,Induction of apoptosis in human A549 cells assessed as necrotic cells at 5 uM after 48 hrs by annexin V/PI staining-based FACS analysis (Rvb = 2.8 %),annexin V/PI staining-based FACS analysis,flow cytometry,BAO_0000005
1339546,F,Induction of apoptosis in human A549 cells assessed as necrotic cells at 5 uM after 48 hrs by annexin V/PI staining-based FACS analysis (Rvb = 2.8 %),annexin V/PI staining-based FACS analysis,Annexin V apoptosis assay,BAO_0010265
2145610,F,Induction of apoptosis in mouse GL261 cells assessed as early apoptotic cells at 50 uM measured after 24 hrs by annexin V-FITC/propidium iodide staining based flow cytometry analysis (Rvb = 1.61%),annexin V-FITC/propidium iodide staining based flow cytometry analysis,propidium iodide DNA staining,BAO_0002476
2145610,F,Induction of apoptosis in mouse GL261 cells assessed as early apoptotic cells at 50 uM measured after 24 hrs by annexin V-FITC/propidium iodide staining based flow cytometry analysis (Rvb = 1.61%),annexin V-FITC/propidium iodide staining based flow cytometry analysis,flow cytometry,BAO_0000005
2145610,F,Induction of apoptosis in mouse GL261 cells assessed as early apoptotic cells at 50 uM measured after 24 hrs by annexin V-FITC/propidium iodide staining based flow cytometry analysis (Rvb = 1.61%),annexin V-FITC/propidium iodide staining based flow cytometry analysis,Annexin V apoptosis assay,BAO_0010265
2088061,F,Induction of apoptosis in human A-375 cells assessed as necrotic cells at 2 uM incubated for 48 hrs by annexin V-FITC and PI staining based flow cytometry (Rvb = 0.139 %),annexin V-FITC and PI staining based flow cytometry,propidium iodide DNA staining,BAO_0002476
2088061,F,Induction of apoptosis in human A-375 cells assessed as necrotic cells at 2 uM incubated for 48 hrs by annexin V-FITC and PI staining based flow cytometry (Rvb = 0.139 %),annexin V-FITC and PI staining based flow cytometry,flow cytometry,BAO_0000005
2088061,F,Induction of apoptosis in human A-375 cells assessed as necrotic cells at 2 uM incubated for 48 hrs by annexin V-FITC and PI staining based flow cytometry (Rvb = 0.139 %),annexin V-FITC and PI staining based flow cytometry,Annexin V apoptosis assay,BAO_0010265
2067582,F,Induction of apoptosis in human HCC827 cells assessed as early apoptotic cells at 1 uM measured after 24 hrs by Annexin V-FITC/propidium iodide staining based flow cytometry (Rvb = 2.49%),Annexin V-FITC/propidium iodide staining based flow cytometry,propidium iodide DNA staining,BAO_0002476
2067582,F,Induction of apoptosis in human HCC827 cells assessed as early apoptotic cells at 1 uM measured after 24 hrs by Annexin V-FITC/propidium iodide staining based flow cytometry (Rvb = 2.49%),Annexin V-FITC/propidium iodide staining based flow cytometry,flow cytometry,BAO_0000005
2067582,F,Induction of apoptosis in human HCC827 cells assessed as early apoptotic cells at 1 uM measured after 24 hrs by Annexin V-FITC/propidium iodide staining based flow cytometry (Rvb = 2.49%),Annexin V-FITC/propidium iodide staining based flow cytometry,Annexin V apoptosis assay,BAO_0010265
1869875,F,Induction of apoptosis in human A549 cells assessed as early apoptotic cells at 2.5 uM after 12 hrs by Annexin V-FITC/propidium iodide staining-based flow cytometric analysis (Rvb = 7.19%),Annexin V-FITC/propidium iodide staining-based flow cytometric analysis,propidium iodide DNA staining,BAO_0002476
1869875,F,Induction of apoptosis in human A549 cells assessed as early apoptotic cells at 2.5 uM after 12 hrs by Annexin V-FITC/propidium iodide staining-based flow cytometric analysis (Rvb = 7.19%),Annexin V-FITC/propidium iodide staining-based flow cytometric analysis,flow cytometry,BAO_0000005
1869875,F,Induction of apoptosis in human A549 cells assessed as early apoptotic cells at 2.5 uM after 12 hrs by Annexin V-FITC/propidium iodide staining-based flow cytometric analysis (Rvb = 7.19%),Annexin V-FITC/propidium iodide staining-based flow cytometric analysis,Annexin V apoptosis assay,BAO_0010265
1844213,F,Induction of apoptosis in human HCT116 cells assessed as viable cells at 0.5 uM by Annexin-V FITC/propidium iodide staining-based flow cytometry (Rvb = 93.4 %),Annexin-V FITC/propidium iodide staining-based flow cytometry,propidium iodide DNA staining,BAO_0002476
1844213,F,Induction of apoptosis in human HCT116 cells assessed as viable cells at 0.5 uM by Annexin-V FITC/propidium iodide staining-based flow cytometry (Rvb = 93.4 %),Annexin-V FITC/propidium iodide staining-based flow cytometry,flow cytometry,BAO_0000005
1844213,F,Induction of apoptosis in human HCT116 cells assessed as viable cells at 0.5 uM by Annexin-V FITC/propidium iodide staining-based flow cytometry (Rvb = 93.4 %),Annexin-V FITC/propidium iodide staining-based flow cytometry,Annexin V apoptosis assay,BAO_0010265
1330988,F,Growth inhibition of human MDA-MB-231 cells assessed as cell growth at 10'-5 M after 48 hrs by sulforhodamine B assay,sulforhodamine B assay,sulforhodamine B staining,BAO_0002460
1284858,F,Growth inhibition of human OVCAR8 cells after 48 hrs by sulforhodamine B assay,sulforhodamine B assay,sulforhodamine B staining,BAO_0002460
987775,F,Growth inhibition of human NCI-ADR-RES cells assessed as cell growth at 10'-5 M after 48 hrs by sulforhodamine B assay relative to control,sulforhodamine B assay,sulforhodamine B staining,BAO_0002460
966269,F,Cell cycle arrest in human MGC803 cells assessed as reduction in G1 phase accumulation after 12 to 24 hrs by propidium iodide staining-based flow cytometry,propidium iodide staining-based flow cytometry,propidium iodide DNA staining,BAO_0002476
966269,F,Cell cycle arrest in human MGC803 cells assessed as reduction in G1 phase accumulation after 12 to 24 hrs by propidium iodide staining-based flow cytometry,propidium iodide staining-based flow cytometry,flow cytometry,BAO_0000005
964025,F,Cell cycle arrest in human Bel7402 cells assessed as accumulation at S phase at 0.15 uM after 48 hrs by propidium iodide staining-based FACS analysis (Rvb = 39.17 %),propidium iodide staining-based FACS analysis,propidium iodide DNA staining,BAO_0002476
964025,F,Cell cycle arrest in human Bel7402 cells assessed as accumulation at S phase at 0.15 uM after 48 hrs by propidium iodide staining-based FACS analysis (Rvb = 39.17 %),propidium iodide staining-based FACS analysis,flow cytometry,BAO_0000005
945494,F,Growth inhibition of human COLO205 cells after 48 hrs by sulforhodamine B assay,sulforhodamine B assay,sulforhodamine B staining,BAO_0002460
857664,F,Growth inhibition of human MDA-MB-231 cells after 72 hrs by celltiter-blue viability assay,celltiter-blue viability assay,CellTiter-Blue Cell Viability Assay (Promega),BAO_0140012
825615,F,Growth inhibition of human CCRF-CEM cells assessed as cell growth at 10'-5 M after 48 hrs by SRB assay,SRB assay,sulforhodamine B staining,BAO_0002460
796334,F,Cell cycle arrest in human SK-BR-3 cells assessed as accumulation at G2/M phase at 0.25 uM after 18 hrs using propidium iodide staining by FACS analysis,propidium iodide staining by FACS analysis,propidium iodide DNA staining,BAO_0002476
796334,F,Cell cycle arrest in human SK-BR-3 cells assessed as accumulation at G2/M phase at 0.25 uM after 18 hrs using propidium iodide staining by FACS analysis,propidium iodide staining by FACS analysis,flow cytometry,BAO_0000005
746641,F,Induction of apoptosis in human Raji cells assessed as late apoptotic or secondary necrotic cells at 10 uM after 24 hrs by measuring phosphatidylserine translocation using annexin V-FITC/propidium iodide staining by FACS (Rvb = 2.2 %),annexin V-FITC/propidium iodide staining by FACS,propidium iodide DNA staining,BAO_0002476
746641,F,Induction of apoptosis in human Raji cells assessed as late apoptotic or secondary necrotic cells at 10 uM after 24 hrs by measuring phosphatidylserine translocation using annexin V-FITC/propidium iodide staining by FACS (Rvb = 2.2 %),annexin V-FITC/propidium iodide staining by FACS,flow cytometry,BAO_0000005
746641,F,Induction of apoptosis in human Raji cells assessed as late apoptotic or secondary necrotic cells at 10 uM after 24 hrs by measuring phosphatidylserine translocation using annexin V-FITC/propidium iodide staining by FACS (Rvb = 2.2 %),annexin V-FITC/propidium iodide staining by FACS,Annexin V apoptosis assay,BAO_0010265
660786,F,Cell cycle arrest in human U2OS cells overexpressing human KRAS2 assessed as accumulation at G1 phase at 15 nM after 48 hrs by CMV-GFP reporter assay method,CMV-GFP reporter assay method,fluorescent protein reporter gene assay,BAO_0003012
631920,F,Cell cycle arrest in human A2780 cells assessed as accumulation at subG1 phase at 0.5 uM after 24 hrs by propidium iodide staining-based FACS analysis,propidium iodide staining-based FACS analysis,propidium iodide DNA staining,BAO_0002476
631920,F,Cell cycle arrest in human A2780 cells assessed as accumulation at subG1 phase at 0.5 uM after 24 hrs by propidium iodide staining-based FACS analysis,propidium iodide staining-based FACS analysis,flow cytometry,BAO_0000005
220135,F,Inhibition of aggregation of human gel-filtered platelets measured by light transmittance method at 37 degrees C.,light transmittance method,transmittance,BAO_0000071
2237671,F,Cytotoxicity against human LXFL 529 cells assessed as cell growth inhibition measured after 3 days by SRB assay,SRB assay,sulforhodamine B staining,BAO_0002460
2210918,F,Cytotoxicity against human MCF7 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay,MTT assay,MTT reduction assay,BAO_0002457
2192958,F,Cytotoxicity against human HT-29 cells incubated for 72 hrs by MTT assay,MTT assay,MTT reduction assay,BAO_0002457
2013313,F,Cytotoxicity against human SK-MEL-28 cells assessed as cell viability at 10 uM incubated for 48 hrs by sulforhodamine B assay relative to control,sulforhodamine B assay,sulforhodamine B staining,BAO_0002460
1867223,F,Cytotoxicity against human HCT116 cells afte r18 hrs by MTT assay,MTT assay,MTT reduction assay,BAO_0002457
1843592,F,Cytotoxicity against human HeLa 229 cells measured after 48 hrs by MTT assay,MTT assay,MTT reduction assay,BAO_0002457
1798872,F,Cytotoxicity in human NCI-H446 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay,MTT assay,MTT reduction assay,BAO_0002457
1692148,F,Cytotoxicity against human SH-SY5Y cells assessed as reduction in cell viability after 4 hrs by MTT assay,MTT assay,MTT reduction assay,BAO_0002457
1671992,F,Cytotoxicity against human MCF7 cells by MTT assay,MTT assay,MTT reduction assay,BAO_0002457
1667363,F,Potentiation of 0.316 uM cisplatin-induced cytotoxicity against human CAL27 cells assessed as decrease in cell viability by measuring combination index at 900 uM preincubated for 48 hrs followed by cisplatin treatment measured after 72 hrs by MTT assay,MTT assay,MTT reduction assay,BAO_0002457
1589315,F,Cytotoxicity against human KB cells assessed as reduction in cell viability at >50 ug/ml by resazurin microplate assay,resazurin microplate assay,resazurin reduction assay,BAO_0002459
1582930,F,Cytotoxicity against human HepG2 cells assessed as cell growth inhibition after 72 hrs by MTT assay,MTT assay,MTT reduction assay,BAO_0002457
953228,F,Cytotoxicity against human A549/ATCC cells after 48 hrs by SRB assay,SRB assay,sulforhodamine B staining,BAO_0002460
770814,F,Cytotoxicity against human UACC62 cells after 48 hrs by SRB assay,SRB assay,sulforhodamine B staining,BAO_0002460
651820,F,Cytotoxicity against human KB cells after 72 hrs by MTT assay,MTT assay,MTT reduction assay,BAO_0002457
620370,F,Cytotoxicity against human NCI-H23 cells assessed as cell growth at 0.1 uM after 1 to 11 days by MTT assay,MTT assay,MTT reduction assay,BAO_0002457
549577,F,Cytotoxicity against human HL60 cells after 48 hrs by MTT assay,MTT assay,MTT reduction assay,BAO_0002457
544150,F,Cytotoxicity against human MCF7 cells by SRB assay,SRB assay,sulforhodamine B staining,BAO_0002460
513447,F,Cytotoxicity against human HOP62 cells assessed as age growth inhibition at 100 uM after 48 hrs by sulforhodamine B assay,sulforhodamine B assay,sulforhodamine B staining,BAO_0002460
439762,F,Cytotoxicity against human LNCaP cells after 72 hrs by SRB assay,SRB assay,sulforhodamine B staining,BAO_0002460
1736751,F,Downregulation of CXCL2 mRNA expression level in human MONO-MAC-6 cells at 5 uM incubated for 30 mins measured after 2 hrs by qRT-PCR method relative to control,qRT-PCR method,quantitative reverse transcription PCR,BAO_0002090
1701883,F,Increase in OPG mRNA expression in mouse MC3T3-E1 cells up to 4 uM after 48 hrs in presence of ascorbic acid and beta-glycerophosphate by real-time PCR analysis,real-time PCR analysis,real-time PCR,BAO_0002084
1615232,F,Effect on KIF11 gene expression in serum-starved HUVEC after 6 hrs by microarray analysis relative to control,microarray analysis,Microarray,BAO_0010048
1615230,F,Effect on ITGB2 gene expression in serum-starved HUVEC after 6 hrs by microarray analysis relative to control,microarray analysis,Microarray,BAO_0010048
555490,F,Decrease in CGD gene ortholog accession number orf19.409 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control,microarray based transcriptional profiling,Microarray,BAO_0010048
554919,F,Decrease in CGD gene ortholog accession number orf19.6211 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control,microarray based transcriptional profiling,Microarray,BAO_0010048
548548,F,Inhibition of LPS and INF-gamma-induced iNOS mRNA expression in mouse RAW264.7 cells by RT-PCR analysis,RT-PCR analysis,reverse transcription PCR,BAO_0002089
2202607,F,Downregulation of MMP9 protein expression in human HepG2 cells at 25 to 50 uM incubated for 24 hrs by Western blot analysis,Western blot analysis,western blot,BAO_0002424
1907990,F,Induction of YqiG protein expression in Bacillus subtilis 168 at 2.3 uM incubated for 15 mins by 35S-methionine pulse labeling based 2D-PAGE analysis,35S-methionine pulse labeling based 2D-PAGE analysis,PAGE,BAO_0010019
1539358,F,"Effect on LKB1 expression in mouse 3T3L1 cells at 0.2 mM after 10 mins, 2 and 24 hrs by western blot analysis",western blot analysis,western blot,BAO_0002424
729351,F,Effect on glutathione peroxidase expression in human A549 cells assessed as transcript level at 662 nM after 24 hrs by RT-qPCR analysis relative to untreated control,RT-qPCR analysis,quantitative reverse transcription PCR,BAO_0002090
442702,F,Inhibition of TNF-alpha-induced E-selectin expression in HUVEC cells at 90 ug/ml after 2 hrs by flow cytometry,flow cytometry,flow cytometry,BAO_0000005
735687,F,Induction of change in cytochrome c protein level in iTRAQ114 labelled secreted fraction of drug-resistant Aspergillus fumigatus EMFR-S678P at 0.12 ug/ml after 24 hrs in YPD medium by MS (MS/MS) analysis relative to control,MS (MS/MS) analysis,mass spectrometry,BAO_0000055
1283562,F,Antiinflammatory activity in human THP1 cells assessed as inhibition of TPA/ionomycin-induced extracellular IL-1beta level at 3 uM incubated 1 hr prior to TPA/ionomycin challenge measured after 24 hrs by ELISA,ELISA,ELISA,BAO_0000134
1337555,F,Neuroprotective activity in glutamate-induced mouse HT22 cells assessed as decrease in ROS level at 1 uM after 12 hrs by H2DCF diacetate-based flow cytometric analysis,H2DCF diacetate-based flow cytometric analysis,flow cytometry,BAO_0000005
1659245,F,"Antimalarial activity against Plasmodium yoelii YM infected in BALB/c mouse assessed as parasite cure level at 10 to 90 mg/kg, ip administered on days 1 post infection by Giemsa-stained microscopic analysis",Giemsa-stained microscopic analysis,microscopy,BAO_0002526
991378,F,"Antimalarial activity against Plasmodium berghei ANKA infected in NMRI mouse assessed as reduction of parasitemia at 10 mg/kg, po qd administered 3 days by flow cytometric analysis",flow cytometric analysis,flow cytometry,BAO_0000005
1545991,F,Antiangiogenic activity in po dosed Brown Norway rat laser-induced choroidal neovascularization model assessed as inhibition of neovascular lesion formation administered qd for 14 days by microscopic analysis,microscopic analysis,microscopy,BAO_0002526
1659644,F,"Inhibition of LTB4 biosynthesis in LPS-induced C57BL/6 mouse model of acute lung injury BLAF at 25 mg/kg, ip by ELISA",ELISA,ELISA,BAO_0000134
1734787,F,"Agonist activity at human kappa opioid receptor expressed in HEK293 assessed as inhibition forskolin-induced cAMP accumulation at 1 uM after 15 mins in presence of U50,488 by EIA",EIA,immunoassay,BAO_0000129
876226,F,Agonist activity at rat mGlu8R expressed in HEK293 cells co-expressing GIRK channels by thallium flux assay,thallium flux assay,,
603084,F,Agonist activity at human 5HT1A receptor expressed in CHO cells by [35S]GTPgammaS binding assay,[35S]GTPgammaS binding assay,,
1630356,F,Bactericidal activity against Mycobacterium smegmatis MC2 155 assessed as log reduction in bacterial colonies at 4 times MIC measured after 24 hrs by time-kill assay,,,
923116,F,Antibacterial activity against Staphylococcus aureus ATCC 25923 assessed as diameter of growth inhibition zone at 100 ug/ml after 24 hr by cup-plate method,cup-plate method,,
841245,F,Antibacterial activity against Listeria innocua after 24 hrs by microtitre plate reader,,,
819365,F,Antibacterial activity against Bacillus subtilis ATCC 6633 assessed as partial clear inhibition zone at 50 uL of 2 mM solution of compound in 1:9 DMSO/MeOH after 24 hrs by agar diffusion method,agar diffusion method,,
795125,F,Antibacterial activity against Bacillus at 10 mg/ml after 24 hrs by cut-plug method,cut-plug method,,
758945,F,Antibacterial activity against Escherichia coli ATCC 8739 at 2 mg/ml after 24 hrs by agar-well diffusion technique,agar-well diffusion technique,,
708614,F,Bactericidal activity against Pseudomonas aeruginosa isolate 956 at 1/4 times MIC after 24 hrs by time kill analysis,,,
477028,F,Antibacterial activity against Staphylococcus aureus ATCC 25923 at 400 ug/disc after 18 hrs by disc diffusion assay,disc diffusion assay,,
480847,F,Antitumor activity against Agrobacterium tumefaciens-induced crown gall tumors assessed as inhibition of tumor development in potato by crown gall tumor potato disk test,crown gall tumor potato disk test,,
2049002,F,Antifungal activity against Candida albicans ATCC 90028 assessed as reduction in microbial growth after 18 to 24 hrs by CLSI based method,CLSI based method,,
983824,F,Antifungal activity against Saccharomyces cerevisiae MTCC 36 at 50 ug/ml after 48 hrs by agar well diffusion method,agar well diffusion method,,
926118,F,Antifungal activity against sithiofam-sensitive Gaeumannomyces graminis var. tritici isolate HN21 expressing C2 genetic cluster assessed as reduction in fungal colony diameter after 4 days,,,
855142,F,Fungicidal activity against Trichoderma viride CECT 2423 at 0.2 mg/disk after 48 hrs by agar diffusion assay,agar diffusion assay,,
720628,F,"Antimalarial activity against Plasmodium falciparum NF54 by [3H]hypoxanthine incorporation assay in presence of 4-oxo-2,2,6,6,-tetramethyl-1-piperidinyloxy",[3H]hypoxanthine incorporation assay,radiometry method,BAO_0000657
507750,F,Antiparasitic activity against Toxoplasma gondii infected in HFF cells at 1 uM after 24 hrs by [3H]uracil incorporation assay relative to control,[3H]uracil incorporation assay,radiometry method,BAO_0000657
2019174,F,Antiviral activity against ETV-resistant and adenovirus AdH294-7LR harboring wild-type HBV infected in human HepG2 cells assessed as reduction in viral replicative intermediate DNAs at 4 to 1000 nM incubated for 5 days by Southern blot analysis,Southern blot analysis,,
713773,F,Antiviral activity against Influenza A virus (A/Vietnam/1203/2004 (H5N1)) infected in MDCK cells selected at 5 nM of zanamivir after 2 passage after 48 hrs by hemagglutininin titer assay,hemagglutininin titer assay,,
102351,F,"Dose required to achieve 50% protection of MT-4 cells from HIV-1(IIIB) induced cytopathogenicity, determined by MIT method.",MIT method,,
926224,F,Inhibition of Nitrosomonas europaea ATCC 25978-mediated nitrification activity assessed as nitrite nitrogen formation at 0.5 mg/kg after 7 to 10 days by Griess-Ilosvay method relative to control,Griess-Ilosvay method,,
1739254,F,Antioxidant activity assessed as ferric ion reducing activity by measuring Fe2+ levels at 10 uM using Fe2+-TPTZ after 15 mins by FRAP assay,FRAP assay,,
924368,F,Herbicidal activity against Monochoria vaginalis assessed as weed control in transplanted rice field at 30 g/ha treated after 15 days transplanting,,,
486467,F,Phytotoxicity against Johnsongrass assessed as leaf necrotic lesions at 100 ug by detached leaf spot method,detached leaf spot method,,
1724375,F,Antiproliferative activity against human LNCAP cells after 48 hrs by CCK-8 assay,CCK-8 assay,,
2188161,F,Antiproliferative activity against human SNU-16 cells assessed as inhibition of cell proliferation incubated for 5 days by CCK-8 assay,CCK-8 assay,,
2154913,F,Cytotoxicity against human Ramos cells assessed as cell death incubated at 10 uM for 20 hrs measured by DNS assay,DNS assay,,
1928863,F,Cytotoxicity against human A549 cells assessed as cell survival up to 10 uM incubated for 24 hrs by CCK8 assay,CCK8 assay,,
1461457,F,Cytotoxicity against human A673 cells after 96 hrs by MTS assay,MTS assay,MTS reduction assay,BAO_0002456
2156446,F,NO releasing activity assessed as NO release efficiency at 100 uM by Griess assay relative to NaNO2,Griess assay,,
1984949,F,Antiinflammatory activity in mouse T cells assessed as inhibition of conA-induced induced T cell proliferation at 2 uM incubated for 48 hrs by CCK8 assay relative to control,CCK8 assay,,
1521285,F,Antileishmanial activity against Leishmania donovani MHOM/IN/80/Dd8 expressing luciferase reporter gene infected in mouse J-774A1 cells assessed as inhibition of amastigote stage formation incubated for 72 hrs by luminometry,luminometry,luminescence method,BAO_0000045
2054967,F,Antiallodynic activity in oxaliplatin-induced peripheral neuropathy pain CD-1 mouse model assessed as inhibition of late-phase tactile allodynia by measuring pain sensitivity threshold at 22.5 mg/kg administered with compound intraperitoneally at 7 days after oxaliplatin stimulation and measured after 30 mins by von Frey test (Rvb = 65.3%),von Frey test,,
1935982,F,"Anti-inflammatory activity in Wistar (Krf:(WI) WU) rat model of carrageenan-induced thermal hyperalgesia assessed as paw withdrawal latency time at 50 mg/kg, ip administered as single dose prior to carrageenan challenge and measured after 2 hrs by plantar test (Rvb = 4.03 +/- 0.7 s)",plantar test,,
1890195,F,"Antialzhemeric activity in Wistar rat model of scopolamine-induced cognition deficit assessed as effect on time in target sector at 100 nM, icv dosed 60 mins prior to training trial by Morris water maze test",Morris water maze test,,
1862272,F,"Antiinflammatory activity in Wistar albino rat assessed as reduction in carrageenan-induced paw volume at 12.5 mg/kg, ip measured after 1 hr by plethysmometric method (Rvb = 1.43 +/- 0.19 ml)",plethysmometric method,,
110077,F,In vivo anticonvulsant activity in male albino mice using the maximal electroshock (MES) test after intraperitoneal administration; value ranges from 85.7-151,maximal electroshock (MES) test,,
830179,F,"Antimigraine activity in marmosets assessed as inhibition of CGRP-induced increase in facial blood flow at 1 mg/kg, sc administered 30 mins post CGRP-challenge measured up to 105 mins by laser doppler flowmetry",laser doppler flowmetry,laser,BAO_0150033
504534,F,"Anxiolytic-like activity in ddY mouse assessed as ambulatory activity at 1 mg/kg, po for 7 days measured 24 hrs after final drug administration assessed per 5 mins by tilting type ambulometer test",tilting type ambulometer test,,
41183,F,Minimum protective concentration against beta-lactamase in Staphylococcus aureus (95 strain),,,
85499,F,Histamine H2 receptor antagonistic activity at a concentration of 0.3 and 0.1 uM on the isolated guinea pig right atrium.,,,
37110,F,Antagonist activity of compound against Beta-1 adrenergic receptor in isolated guinea pig left atria,,,
61299,F,"D2 receptor functional activity was measured through reversal of quinpirole inhibited, forskolin stimulated cAMP production from whole cells",,,
330729,F,Effect on DBH activity in presence of dopamine by measuring Noradrenaline level,,,
73696,F,Irreversible antagonism to morphine was evaluated after 30 min incubation of GPI with the compound at 1000 nM conc.,,,
27772,F,Antagonism of NECA-induced stimulation of adenylate cyclase activity in human platelet membranes at A2-adenosine receptor; value ranges from 21-30,,,
64839,F,Effect on the activity of elastase was determined,,,
1790107,F,Antibacterial activity against Staphylococcus epidermidis clinical isolate incubated for 16 hrs under shaking condition,,,
1787702,F,Potentiation of erythromycin-induced antibacterial activity against Enterococcus faecium ATCC 700221 assessed as minimum modulatory concentration up to 32 uM measured after 16 hrs in presence of MIC/4 erythromycin,,,
1778761,F,"Potency index, ratio of cefaclor MIC to compound MIC for methicillin-resistant Staphylococcus aureus NRS70",,,
709641,F,Antibacterial activity against Escherichia coli DSM 498,,,
677042,F,"FIC index, ratio of MIC for Pseudomonas aeruginosa 100609 in presence of 250 ug/ml polyethylenimine to MIC for Pseudomonas aeruginosa 100609",,,
580428,F,Antibacterial activity against Clostridium difficile CD5 expressing tet(W) gene,,,
576943,F,Antibacterial activity against gentamicin-treated internalized Escherichia coli isolate HM605 in mouse J774A1 cells isolated from colonic mucosal biopsies of patient with Crohn's disease assessed as intracellular killing of bacteria at 18 ug/ml after 6 hrs,,,
574044,F,Antibacterial activity against daptomycin-nonsusceptible Staphylococcus aureus isolate 703 bloodstream form isolated from patient with endocarditis assessed as bacterial survival rate at 20 ug/ml after 2 hrs,,,
426791,F,Antibacterial activity against methicillin-resistant Staphylococcus aureus B42876,,,
422259,F,Antibacterial activity against Bacillus subtilis,,,
313538,F,Ratio of the MIC value of the Mycobacterium tuberculosis ) isoniazid resistant strain to H37Rv strain was determined,,,
213894,F,Antibacterial activity against Vibrio cholerae 0139,,,
203511,F,In vitro minimum inhibitory concentration against Staphylococcus epidermis ATCC 12228,,,
66816,F,Minimum inhibitory concentration required for antibacterial activity against Escherichia coli 10418,,,
1475850,F,Antimycobacterial activity against Mycobacterium sp.,,,
580793,F,Antimicrobial activity against vancomycin-resistant Staphylococcus aureus isolate 13,,,
441160,F,Antimicrobial activity against Escherichia coli MC4100 assessed as inhibition zone at >2 mg/mL,,,
681843,F,Antimicrobial activity against Legionella pneumophila ATCC 33153 infected in THP1 cells after 48hrs,,,
1759988,F,Growth inhibition of Candida albicans at 32 ug/ml,,,
1291412,F,Growth inhibition of Saccharomyces cerevisiae BY4742 harboring gcn5delta mutant after 48 hrs,,,
892427,F,Antifungal activity against Rhizoctonia solani assessed as inhibition of mycelium growth after 2 days,,,
157141,F,Accumulation coefficient of chloroquine at 1 uM-10 uM of DEEA against Plasmodium falciparum W2; Range is from 14-56,,,
155626,F,In vitro antimalarial activity against chloroquine-sensitive Plasmodium falciparum D6 (CDC/Sierra Leone I); Not active,,,
102812,F,Antiprotozoal activity (functional assay) using Mauden-Downing bovine kidney (MDBK) host cells infected with Eimeria tenella,,,
919254,F,Antiviral activity against Tobacco mosaic virus (TMV) inoculated in whole leaves of Nicotiana tabacum L. assessed as curative effect measured as local lesion number at 50 mg/l after 3 to 4 days,,,
743655,F,Antiviral activity against wild type HIV1 3B infected in human CEM cells assessed as inhibition of syncytia formation,,,
705805,F,Ratio of EC50 for HIV1 TM harboring L10I/K14R/R41K/M46L/I54V/L63P/A71V/V82A/L90M/I93L in protease encoding region to EC50 for HIV1 ERS104pre,,,
648420,F,Ratio of acyclovir EC50 to compound EC50 for HSV 2 infected in african green monkey Vero cells,,,
432490,F,Antiviral activity against hepatitis C virus,,,
196812,F,Effect on replication of FIV 34TF10env in chronically infected feline glial cell lines G355-5 at 1000 nM conc; RT activity per ug/mL of protein concentration,,,
103748,F,Inhibitory concentration against AD169 strain of HCMV in MRC5 cells,,,
82611,F,Antiviral activity against herpes simplex virus type I was measured at 5 uM concentration.,,,
1798774,F,Antioxidant activity assessed as carbon-centered lipid radical scavenging activity in presence of t-butylalcohol solvent,,,
976258,F,Antioxidant activity assessed as DPPH radical scavenging activity at 40 uM after 30 mins,,,
834886,F,Antioxidant activity assessed as inhibition of DPPH radical at 1 to 20 mM after 15 mins,,,
809816,F,Antioxidant activity using deaerated 1 M ethylene glycol as substrate assessed as hydroxy radical additive level at 1 mmol/L after gamma-irradiation,,,
308660,F,Dissociation constant was measured against HIV-1 RNA construct F (present in HIV-1 RRE IIB RNA region); N.B. = no measurable binding,,,
14978,F,Dissociation constant against constrictor response to the compound blocked competitively by phentolamine for alpha-mediated events,,,
70429,F,Concentration required to displace 50% of a radiolabeled farnesyltransferase inhibitor from FPTase in cultured Ha-Ras transformed RAT1 cells,,,
475573,F,Increase in acetylated alpha tubulin level in human HCT116 cells at 10 uM after 24 hrs relative to control,,,
96879,F,Inhibition of glycogen synthesis in rat skeletal muscle L6 cells (inactive),,,
95086,F,Concentration inhibiting radiolabeled spermidine transport in L1210 cells.,,,
87333,F,Potency relative to progesterone in reducing the difference in reversal of DOX accumulation between MDA-435/LCC6 and MDA-435/LCC6-MDRI cells,,,
40592,F,Percent growth of breast MCF-7 cell line at compound concentration 10e-6 was determined,,,
2229996,F,Antiproliferative against in mouse BaF3 EFGR Del19/T790M/C797S cell,,,
619315,F,Antiproliferative activity against human CCRF-CEM cells at 10 uM assessed as cell growth inhibition relative to control,,,
346375,F,Antiproliferative activity against resistant CCRF-CEM/VBL cell line,,,
1368390,F,"Relative resistance, ratio of IC50 for human SKOV3 cells expressing MDR1/M-6-6 to IC50 for human SKOV3 cells",,,
1334710,F,Growth inhibition of human NCI-H226 cells,,,
1331128,F,Growth inhibition of human MDA-MB cells,,,
441740,F,Growth inhibition of DLA cells at 62.5 ug/mL after 3 hrs,,,
311495,F,Growth inhibition against human pancreas carcinoma cell line (BxPC-3); (NT = Not tested),,,
212438,F,inhibition of the growth of renal cancer(UO-31) cell line,,,
151851,F,In vitro inhibitory activity against human PANC-1 pancreatic tumor; Active,,,
92634,F,Effective dose to inhibit FasL-induced apoptosis in Jurkat cells (Type II); NE=no effect,,,
78652,F,Inhibitory activity against HL 60 cells,,,
68829,F,Cell growth of friend erythroleukemia cells measured as percentage of control on day 6 at a concentration of 105 mM,,,
715883,F,Cytotoxicity against human HNXF 536L cells at 10 ug/ml relative to control,,,
533302,F,Cytotoxicity against human Hs 633T cells at 2 uM assessed as fraction of viable cells after 72 hrs relative to control,,,
507009,F,Cytotoxicity against human A2780 cells,,,
506850,F,Cytotoxicity against human MDA-MB-435 cells,,,
502968,F,Cytotoxicity against human SNB19 cells,,,
401203,F,Cytotoxicity against HEK293 cells relative to control,,,
311581,F,Cytotoxicity against A549 cell line,,,
88744,F,Cytotoxic activity against human neuroblastoma IMR32 cells which over-express somatostatin receptors; na is not active,,,
75628,F,Cytotoxicity against a human colon cancer cell line (HCT116 cells) was reported,,,
926445,F,Decrease in Botryosphaeria dothidea ligninolytic enzyme production assessed as laccase activity using ABTS as substrate at 25 mM measured at 28 degC after 4 days,,,
148037,F,"Antitumor activity against P338 leukemia cells measured as toxic level at 3.12 mg/kg, ip optimal dose on days 1-5 in mice",,,
167325,F,Opioid agonist activity by measuring the analgesia produced after 10 mg/kg administration in rats; none,,,
1765481,F,In-vivo binding affinity to transthyretin in beagle dog serum assessed as protein occupancy 5 mg/kg/day dosed daily dosed as single administration via oral gavage,,,
877041,F,"Inhibition of mTORC1 in human PC3 cells xenografted mouse assessed as reduction of phosphorylated p70S6K level at 25 to 100 mg/kg, po after 6 hrs",,,
795958,F,"Inhibition of human recombinant MMP12-induced lung inflammation in C57BL/6 mouse assessed as reduction in bronchoalveolar lavage inflammation at 5 mg/kg, po bid at 2 hrs prior to and 12 hrs post challenge measured 24 hrs after last challenge relative to vehicle treated control",,,
473897,F,"Antimycobacterial activity against Mycobacterium tuberculosis ATCC 35801 infected in CD1 mouse assessed as bacterial load in spleen at 25 mg/kg, ip after 10 days",,,
576733,F,"Antifungal activity against 1.04 x 10'8 CFU Candida glabrata isolate 4293 infected in CD1 mouse assessed as inhibition of regrowth in fungal burden in kidney at 1 mg/kg/day, ip administered from day 1 to day 2 post viral challenge measured on day 7 postinfection",,,
1773499,F,Antifungal activity against Candida albicans ATCC 90028 infected in Galleria mellonella larvae infected with 20 uM compound pre-treated cell suspensions assessed as melanization incubated in dark for 144 hrs at 30 degC and measured every 24 hrs (Rvb = 65%),,,
939587,F,"Antimalarial activity against chloroquine, mefloquine and halofantrine-resistant Plasmodium yoelii nigeriensis infected in Swiss mouse assessed as protection against parasite-induced mortality at 24 mg/kg, po administered for 4 days measured on day 28",,,
708208,F,"Trypanocidal activity against Trypanosoma brucei brucei 667 infected in mouse assessed as average day of relapse of trypanosomal infection at 25 mg/kg, ip BID for 14 days",,,
122514,F,Inhibition of Rauscher leukemia virus in female BALB/c mice. Compound is administered perorally at 125 mg/kg for 5 days a week for 4 weeks (exp 1); treated/control= 46.8/46.0,,,
1645352,F,Analgesic activity in CFA-induced mechanical hyperalgesia C57BL/6J mouse model assessed as mechanical paw withdrawal threshold at 3 ug/10 uL administered intrathecally 2 days after CFA injection measured at 90 to 150 mins post dose,,,
2115206,F,"Gastroprokinetic activity in CD-1 mouse assessed as stimulation of gastrointestinal motility by measuring fecal number at 10 mg/kg, po measured after 2 hrs (Rvb = 5.3 +/-0.7 No_unit)",measuring fecal number,visual observation method,BAO_0050002
1931928,F,"Antiinflammatory activity in Sprague-Dawley rat assessed as inhibition of croton oil-induced ear edema at 15 mg/kg, ip administered 1 hr before croton oil challenge measured after 3 hrs post challenge relative to control",,,
1543802,F,"Anticonvulsant activity in CF1 albino mouse assessed as protection against 6 Hz-psychomotor-induced seizure at 50 mg/kg, ip after 4 hrs",,,
834505,F,"Anticonvulsant activity in mouse assessed as protection against subcutaneous pentylenetetrazole-induced seizures at 300 mg/kg, ip after 4 hrs",,,
833701,F,"Antitumor activity against human A549 cells xenografted in nu/nu mouse assessed as inhibition of tumor volume at 3 mg/kg, ip administered three times a week for 3 weeks",,,
37727,F,Median survival time (% T/C) after ip administration of a dose of 4 mg/kg/day in B-16 melanoma in mice,,,
107760,F,Evaluated for survival time of P388 Leukemia implanted female CDF1 Mice at a dose of 25 mg/kg,,,
1338888,F,"Antitumor activity against mouse S180 cells allografted in ddY mouse assessed as tumor growth inhibition at 10 mg/kg, po administered once every 2 days for 2 weeks relative to control",,,
1513272,F,"Antitumor activity against human NCI-H3122 cells xenografted in SCID mouse assessed as tumor growth inhibition at 50 mg/kg, po qd for 14 days",,,
117836,F,Nephrotoxicity upon intragastric administration was assessed in mice kidney as proximal tublar necrosis deep in the cortex at a dose of 10 mM,,,
2160336,F,"Antitumour activity against human LNCaP cells xenografted in CB17 SCID mouse assessed as tumour growth inhibition at 2.5 mg/kg, IT(Intratumoral) administered once in every week for 25 days",,,
1651596,F,"Antitumor activity against mouse H22 cells implanted in Kunming mouse assessed as tumor growth inhibition at 24 mg/kg, ip administered once in every 3 days totally for 3 times relative to control",,,
2170430,F,"Antitumor activity against human Raji cells xenografted in NOD-SCID mouse assessed as tumor growth inhibition at 1.5 mg/kg, po administered for 25 days",,,
185374,F,Effect on urinary excretion potassium and sodium after oral administration of 25 mg/kg to rats(potassium and sodium excretion in control rat is 0.146+/-0.017),,,
125044,F,Uterotrophic activity in immature mouse,,,
1356171,F,Hypolipidemic activity in Wistar rat assessed as reduction in plasma cholesterol level at 499 umol/kg/day administered through diet for 4 days,,,
912047,F,"Hypolipidemic activity in high cholesterol diet fed Mus musculus KM (mouse) assessed as low density lipoprotein cholesterol at 150 mg/kg, ig for 10 days (Rvb = 4.2972 +/- 1.1725 mmol/l)",,,
427950,F,Effect on ratio of total cholesterol to HDL cholesterol in lean Wistar rat at 70 mg/kg/day relative to control,,,
328483,F,Increase of HDL level in cholesterol-fed male rats by ultracentrifugation method at 55 mg/kg/day relative to control,ultracentrifugation method,,
902639,F,"Antihyperlipidemic activity in high fat-high cholesterol fed New Zealand Oryctolagus cuniculus (rabbit) assessed as total cholesterol level in blood at 10 mg/kg, po for 40 days (Rvb = 8.74 +/- 0.53 mmol/l)",,,
820687,F,"Antidyslipidemic activity in fasted beagle dog assessed as reduction in free fatty acid level in plasma at 2 mg/kg, po after 1 hr relative to vehicle-treated control",,,
857710,F,Antiobesity activity in po dosed wild type DIO C57 mouse assessed as reduction of food intake,,,
222348,F,5-HTP accumulation in limbic system was determined in vivo,,,
185993,F,Maximal reduction in percent (Partial response) of DOPA accumulation rat hemispheres at highest test dose of 61 uM/Kg (po); Inactive,,,
186424,F,"Dose-dependent protective activity at 10 mg/kg (po, b.i.d.) on cartilage damage in hind paws of CIA-rats",,,
166452,F,Concentration required to decrease 25% of blood pressure in rat; ED25 not reached at 1.0 mg/kg iv,,,
44934,F,Effective dose required to produce an increase in dP/dt by 1500 mmHg/s from that of the control in the anesthetized cats.,,,
507889,F,"Inhibition of cartilage damage in New Zealand white rabbit osteoarthritis model assessed as reduction of cartilage lesion on femoral condyles at 30 mg/kg, po twice daily after 5 weeks relative to control",,,
151167,F,MST of treated animal over control when administered at a dose of 5 mg/kg intravenously on Q01Dx01 treatment schedule,,,
912430,F,"Antidiabetic activity against STZ-induced diabetic Rattus norvegicus Wistar albino (rat) assessed as change in hemoglobin at 20 mg/kg, po administered via intragastric tube for 45 days (Rvb = 8.5 +/-0.9 mg/dl)",,,
47207,F,Effect of intravenous infusion on diastolic pressure in Anesthetized cats at a dose of 1.50 mg/kg at 10 min,,,
167428,F,"Effect of pretreatment with alpha-MPT on the rotational behavior induced by the compound (5 mg/kg, sc) in rats with 6-OHDA induced lesions (indicates that it acted directly on DA receptors)",,,
1335988,F,"Antihypertensive activity in Wistar rat assessed as mean arterial pressure at 10 mg/kg, ip measured immediately at 0 min (Rvb = 194.08 +/- 1.962 mmHg)",,,
626035,F,Inhibition of capsaicin-induced vasodilation in orally dosed rhesus monkey at 5.5 uM plasma level,,,
909420,F,Anticoagulant activity in Rattus norvegicus Wistar (rat) diabetic-hyperlipidemic model assessed as decrease in TFa activity in aorta measuring clotting time at 10.91% administered through feeding measured after 12 weeks (Rvb = 36.25 +/- 1.39 secs),,,
314632,F,Concentration of C22:2 ceramide in liver of D-galactosamine treated rats after 18 hr at dose of 1 g/kg intraperitoneally,,,
169740,F,"Amount of milk ingested after the 120 min methamphetamine-challenges, produced by the compound at 0.312 mg/kg in fasted rats",,,
615712,F,Antilipolytic activity in po dosed rat assessed as reduction plasma free fatty acids levels,,,
170803,F,"Percent decrease in angiotensin I pressor response was measured in rat, administered intravenously at dose 0.010 mg/kg",,,
189479,F,Percentage of animals emitting 50 presses on the LSD appropriate lever during the test period in rat at 0.02 mg/kg(0.046 uM/kg),,,
1912425,B,Binding affinity to wild-type TTR (unknown origin) assessed as induction of chemical shift at L58 residue at 0.6:1 to 1:1 ratio of compound to protein by 2D TROSY [1H-15N] spectroscopy,2D TROSY [1H-15N] spectroscopy,nuclear magnetic resonance,BAO_0000160
1864118,B,Inhibition of human recombinant full length N-terminal GST tagged p38alpha expressed in baculovirus infected Sf9 cells using p38 peptide as substrate measured after 60 mins in presence of ATP by ADP-Glo kinase assay,ADP-Glo kinase assay,ADP Glo Kinase Assay,BAO_0000690
1558050,B,Inhibition of BRPF3 (unknown origin) by Alpha Screen assay,Alpha Screen assay,alphascreen,BAO_0000130
1750677,B,Binding affinity to human partial length BRD3 bromodomain 2 (G306 to P416 residues) expressed in bacterial expression system by BROMOscan assay,BROMOscan assay,,
1729907,B,Inhibition of recombinant human JAK3 (781 to 1124 residues) expressed in insect cells using 5FAM-GEEPLYWSFPAKKK-NH2 as substrate after 10 mins by caliper assay,caliper assay,,
1551515,B,Inhibition of human EGFR preincubated for 10 mins followed by addition of FAM-labeled peptide and incubated for 10 mins by Caliper motility shift assay,Caliper motility shift assay,,
1934860,B,Inhibition of human biotinylated VEGF-A165 binding to recombinant human NRP1 receptor at 100 uM after 2 hrs by chemiluminescence analysis relative to control,chemiluminescence analysis,chemiluminescence,BAO_0000051
1613700,B,Inhibition of activated protein C (unknown origin) at 37 degC by chromogenic substrate assay,chromogenic substrate assay,,
1717988,B,Activation of ABCG2 ATPase activity (unknown origin) expressed in baculovirus infected high5 cell membranes assessed as enzyme activity at 56 nM after 20 mins by ascorbic acid ammonia molybdate reaction based colorimetric assay relative to control,colorimetric assay,,
2119431,B,Inhibition of vanadate sensitive BCRP ATPase activity in human S1-M1-80 cell membranes preincubated for 30 mins followed by ATP addition and measured after 1 hr by colorimetric assay,colorimetric assay,,
1806100,B,Displacement of biotinylated AVPF from N-terminal His tagged recombinant human XIAP-BIR3 Lys311Ser mutant expressed in Escherichia coli BL21(DE3) cells incubated for 8 hrs by DELFIA,DELFIA,,
2032025,B,Inhibition of human COX2 assessed as reduction in PGF2alpha formation using arachidonic acid as substrate incubated for 10 mins by ELISA,ELISA,ELISA,BAO_0000134
1873995,B,Activation of YFP-tagged TLR2 (unknown origin) expressed in HEK293 cells assessed as induction of IL8 secretion at 8 ug/mL incubated for 16 to 18 hrs by ELISA,ELISA,ELISA,BAO_0000134
1660709,B,Inhibition of TLR9 in human PBMC assessed as reduction in ODN2216-stimulated IFNalpha expression at 1 to 10 uM by ELISA,ELISA,ELISA,BAO_0000134
1825833,B,"Inhibition of recombinant human full-length N-terminal His6-tagged Src expressed in Sf21 insect cells at 1000 nM using poly (Glu, Tyr)4:1 as substrate measured after 1 hr by ELISA relative to control",ELISA,ELISA,BAO_0000134
1651980,B,Poison activity at recombinant human topoisomerase-2alpha expressed in Saccharomyces cerevisiae JEL1 harboring topoisomerase1 deletion mutant assessed as increase in double stranded DNA cleavage at 1 mM using supercoiled pBR322 DNA as substrate preincubated for 1 to 5 mins followed by substrate addition measured after 6 mins by ethidium bromide staining based agarose gel electrophoresis,ethidium bromide staining based agarose gel electrophoresis,ethidium bromide DNA staining,BAO_0002474
1651980,B,Poison activity at recombinant human topoisomerase-2alpha expressed in Saccharomyces cerevisiae JEL1 harboring topoisomerase1 deletion mutant assessed as increase in double stranded DNA cleavage at 1 mM using supercoiled pBR322 DNA as substrate preincubated for 1 to 5 mins followed by substrate addition measured after 6 mins by ethidium bromide staining based agarose gel electrophoresis,ethidium bromide staining based agarose gel electrophoresis,agarose gel,BAO_0010020
1797285,B,Binding affinity to human langerin expressed in human Raji cells preincubated with Cy5 conjugated compound for 2 hrs followed by washing and measured by flow cytometric analysis,flow cytometric analysis,flow cytometry,BAO_0000005
1652717,B,Inhibition of ATP citrate lyase in snail expressing HMLE cells assessed as suppression of cancer stemness by measuring CD44 positive/negative and CD24 positive cells at 10 uM after 48 hrs by flow cytometry (Rvb = 4.85 %),flow cytometry,flow cytometry,BAO_0000005
1691517,B,Inhibition of chymotrypsin-like activity of 20S proteasome in human HL60 cells using Suc-LLVYaminoluciferin as substrate at 2 uM after 2 hrs by fluorescence analysis,fluorescence analysis,fluorescence method,BAO_0000046
2092323,B,Inhibition of recombinant human N-terminal His-tagged HDAC11 expressed in baculovirus infected Sf9 insect cells using Ac-Arg-His-Lys(Ac)-Lys(Ac)-AMC as substrate measured after 30 mins by fluorescence assay,fluorescence assay,fluorescence method,BAO_0000046
1747466,B,Antagonist activity at recombinant human eGFP-fused Ahr expressed in yeast cells co-expressing ARNT assessed as inhibition of benzo(a)pyrene-induced Ahr activation at 1 uM measured after 18 hrs by fluorescence assay,fluorescence assay,fluorescence method,BAO_0000046
1904292,B,"Inhibition of human testis ACE C-domain lacking unique O-glycosylated region, transmembrane anchor and cytoplasmic tail expressed in CHO cells using Z-FHL as substrate by fluorescence based assay",fluorescence based assay,fluorescence method,BAO_0000046
2052178,B,Inhibition of HDAC1 in human HeLa nuclear extract using Boc-Lys(Ac)-AMC as substrate measured after 2 hrs by fluorescence based assay,fluorescence based assay,fluorescence method,BAO_0000046
2053483,B,Inhibition of IDH2 R172K mutant (unknown origin) assessed as reduction in NADPH consumption using alpha-ketoglutarate and NADPH as substrate preincubated with enzyme for 15 mins followed by substrate addition by fluorescence based assay,fluorescence based assay,fluorescence method,BAO_0000046
1807970,B,Inhibition of HDAC10 (unknown origin) using Ac-ArgThr- Lys(Ac)Lys(Ac)-AMC as substrate preincubated for 5 mins followed by substrate addition and measured after 60 mins by fluorescence based assay,fluorescence based assay,fluorescence method,BAO_0000046
2112640,B,Inhibition of N-terminal GST-tagged full length human HDAC6 expressed in baculovirus-infected Sf9 cells using Boc-Lys (acetyl)-AMC as substrate preincubated for 5 mins followed by substrate addition and further incubated for 30 mins by fluorescence based assay,fluorescence based assay,fluorescence method,BAO_0000046
2089693,B,Inhibition of recombinant human HDAC1 using Z-(Ac)Lys-AMC as substrate after 90 mins by fluorescence based micro plate assay,fluorescence based micro plate assay,fluorescence method,BAO_0000046
1877072,B,Displacement of fluorescein labelled Puma-BH3 peptide from His-tagged-TEV fused human Mcl-1 incubated for 2 hrs by fluorescence polarization assay,fluorescence polarization assay,fluorescence polarization,BAO_0000003
2146163,B,Displacement of GDP-BODIPY probe from BTN3A1 full intracellular domain (unknown origin) at 0.1 mM measured after 60 mins by fluorescence polarization assay,fluorescence polarization assay,fluorescence polarization,BAO_0000003
1844860,B,Displacement of 6N-FAM from human LRH1 LBD (299 to 541 residues) expressed in Escherichia coli BL21 pLysS by competitive binding based fluorescence polarization assay,fluorescence polarization assay,fluorescence polarization,BAO_0000003
1704689,B,Inhibition of human recombinant MMP-9 catalytic domain (107 to 449 residues) expressed in Escherichia coli using fluorogenic MOCAc-Pro-Leu-Gly-Leu-A2pr(Dnp)-Ala-Arg-NH2 as substrate at 10 uM by fluorescence spectrophotometric analysis,fluorescence spectrophotometric analysis,fluorescence method,BAO_0000046
2014877,B,Binding affinity to C-terminal 8-His tagged human MMP-9 hemopexin-like domain (Ala20 to Asp707 residues) expressed in 293E cells by fluorescence spectroscopy,fluorescence spectroscopy,fluorescence method,BAO_0000046
2119620,B,Inhibition of recombinant human C-terminal His-tagged HDAC9 (604 to 1066 residues) expressed in baculovirus expression system using Nepsilon-Trifluoroacetyl L-lysine substrate by fluorescent microplate reader assay,fluorescent microplate reader assay,fluorescence method,BAO_0000046
2184782,B,Inhibition of human recombinant HDAC6 using BML-AK511 as substrate incubated for 60 mins by fluorimetric assay,fluorimetric assay,fluorescence method,BAO_0000046
2157377,B,Positive allosteric modulator activity at human MRGPRX1 transfected in HEK293 cells in presence of BAM8-22 by Fulo4AM dye based FLIPR assay,Fulo4AM dye based FLIPR assay,FLIPR Membrane Potential Assay Kit,BAO_0003088
2112257,B,Inhibition of human TDO expressed in HEK293-EBNA cells assessed as reduction in kynurenine formation using tryptophan as substrate at 6.25 uM incubated for 24 hrs by HPLC analysis relative to control,HPLC analysis,HPLC System,BAO_0002733
1621810,B,Inhibition of OGT (unknown origin) assessed as reduction in GlcNAc transfer to CKII peptide at 100 uM incubated for 60 mins by HPLC method,HPLC method,HPLC System,BAO_0002733
2086797,B,Inhibition of Aurora A (unknown origin) incubated for 1 hrs by HTRF assay,HTRF assay,homogeneous time resolved fluorescence,BAO_0000002
2069831,B,Agonist activity at human RXRalpha transfected in human HEK293T cells co-expressing pFR/pRL-Luc at 30 uM incubated for 14 to 16 hrs by hybrid reporter gene assay relative to bexarotene,hybrid reporter gene assay,reporter gene assay,BAO_0003006
2076633,B,Activation of FoxO3A in human MDA-MB-231 cells after 72 hrs by immunoblot analysis,immunoblot analysis,immunoassay,BAO_0000129
2195904,B,Inhibition of UCHL1 in human HEK293 cells using HA-Ub-VME as substrate at 0.1 to 10 uM incubated for 1 hr by immunoblotting analysis,immunoblotting analysis,immunoassay,BAO_0000129
1659301,B,Binding affinity to DYRK1A in human U251 cell lysate preincubated for 1 hr followed by incubation at 54 degreeC for 3 mins by isothermal dose-response fingerprint assay,isothermal dose-response fingerprint assay,,
1670804,B,Binding affinity to recombinant human GFP-fused ERalpha LBD (301 to 553 residues) expressed in Escherichia coli BL21(DE3) in presence of 17beta-estradiol by ITC,ITC,isothermal titration calorimetry,BAO_0000428
1644719,B,Binding affinity to full length recombinant human N-terminal His8-tagged Cyclophilin A (1 to 169 residues) expressed in Escherichia coli BL21(DE3) assessed as change in entropy at 225 to 300 uM by ITC,ITC,isothermal titration calorimetry,BAO_0000428
1816940,B,Binding affinity to recombinant human carbonic anhydrase 13 expressed in Escherichia coli expression system assessed as kinetic gibbs free energy change by ITC method,ITC method,isothermal titration calorimetry,BAO_0000428
2150721,B,Inhibition of TrKC (unknown origin) incubated for 120 mins in presence of 33P-ATP,,,
2210648,B,Reversible inhibition of N-terminal His-tagged human recombinant glycolate oxidase expressed in Escherichia coli BL21 (DE3) cells assessed as enzyme recovery using glycolate as substrate at 100 times of IC50 concentration preincubated for 30 mins followed by substrate addition and measured every 60 sec for 15 mins by jump-dilution based Amplex red and horseradish peroxidase fluorescence assay,jump-dilution based Amplex red and horseradish peroxidase fluorescence assay,fluorescence method,BAO_0000046
2210648,B,Reversible inhibition of N-terminal His-tagged human recombinant glycolate oxidase expressed in Escherichia coli BL21 (DE3) cells assessed as enzyme recovery using glycolate as substrate at 100 times of IC50 concentration preincubated for 30 mins followed by substrate addition and measured every 60 sec for 15 mins by jump-dilution based Amplex red and horseradish peroxidase fluorescence assay,jump-dilution based Amplex red and horseradish peroxidase fluorescence assay,Amplex red reagent,BAO_0001217
2210648,B,Reversible inhibition of N-terminal His-tagged human recombinant glycolate oxidase expressed in Escherichia coli BL21 (DE3) cells assessed as enzyme recovery using glycolate as substrate at 100 times of IC50 concentration preincubated for 30 mins followed by substrate addition and measured every 60 sec for 15 mins by jump-dilution based Amplex red and horseradish peroxidase fluorescence assay,jump-dilution based Amplex red and horseradish peroxidase fluorescence assay,dilution method,BAO_0002418
1778489,B,Binding affinity to partial length human PDGFRA (V575 to D1002 residues) expressed in mammalian expression system by KdELECT assay,KdELECT assay,,
1735937,B,Inhibition of human PIP5K2C expressed in mammalian expression system assessed as remaining enzyme activity at 10 uM by kinome scan assay,kinome scan assay,KINOMEScan assay,BAO_0003011
1578804,B,Inhibition of human ROCK2 (1 to 431 amino acid residues) assessed as enzyme activity at 10 uM by KINOMEScan assay,KINOMEScan assay,KINOMEScan assay,BAO_0003011
1646002,B,Inhibition of human RIPK1 (M1 to K305 residues) expressed in bacterial expression system assessed as residual activity at 1 uM by KINOMEscan assay relative to control,KINOMEscan assay,KINOMEScan assay,BAO_0003011
1679271,B,Binding affinity to partial length human HIPK1 (M146 to I555 residues) expressed in mammalian expression system assessed as unbound drug level at 300 nM by KINOMEscan assay,KINOMEscan assay,KINOMEScan assay,BAO_0003011
1775920,B,Inhibition of full length human MARK3 (M1 to L729 residues) expressed in bacterial expression system assessed as residual activity at 5 uM by KINOMEscan assay relative to control,KINOMEscan assay,KINOMEScan assay,BAO_0003011
1681112,B,Inhibition of human FLT3 K663Q mutant (V592 to Y969 residues) expressed in bacterial expression system assessed as residual activity at 1 uM by Kinomescan assay relative to control,Kinomescan assay,KINOMEScan assay,BAO_0003011
1773592,B,Binding affinity to wild-type human partial length ARK5 (E25 to I332 residues) expressed in bacterial expression system assessed as residual binding level at 1 uM by Kinomescan method relative to control,Kinomescan method,KINOMEScan assay,BAO_0003011
1674858,B,Inhibition of wild-type human ACVR2A (V171 to T499 residues) expressed in bacterial expression system assessed as residual activity at 1 uM by Kinomescan method relative to control,Kinomescan method,KINOMEScan assay,BAO_0003011
1857287,B,Binding affinity to wild-type human partial length NEK10 (L488 to R809 residues) expressed in mammalian expression system assessed as residual binding level at 1 uM by Kinomescan method relative to control,Kinomescan method,KINOMEScan assay,BAO_0003011
1880923,B,Binding affinity to wild-type human partial length CAMKK1 (R65 to E414 residues) expressed in bacterial expression system assessed as residual binding level at 1 uM by Kinomescan method relative to control,Kinomescan method,KINOMEScan assay,BAO_0003011
1692973,B,Inhibition of wild-type human full length CDK3 (M1 to H305 residues) expressed in Escherichia coli BL21 assessed as residual activity at 1000 nM after 30 mins by Kinomescan method relative to control,Kinomescan method,KINOMEScan assay,BAO_0003011
1792490,B,Binding affinity to wild-type human partial length MLK3 (I77 to W399 residues) expressed in bacterial expression system assessed as remaining unbound target protein level at 1000 nM by Kinomescan method relative to control,Kinomescan method,KINOMEScan assay,BAO_0003011
1751032,B,Binding affinity to wild-type human partial length EPHB3 (Q599 to T928 residues) expressed in Escherichia coli BL21 at 1 uM by Kinomescan method relative to control,Kinomescan method,KINOMEScan assay,BAO_0003011
1751313,B,Binding affinity to wild-type human partial length TAOK2 (M1 to A320 residues) expressed in HEK293 cells at 1 uM by Kinomescan method relative to control,Kinomescan method,KINOMEScan assay,BAO_0003011
1773635,B,Binding affinity to wild-type human partial length CDK8 (M1 to T360 residues) expressed in bacterial expression system assessed as residual binding level at 1 uM by Kinomescan method relative to control,Kinomescan method,KINOMEScan assay,BAO_0003011
1887987,B,Inhibition of wild-type human partial length DDR1 (R565 to V876 residues) expressed in bacterial expression system at 1 uM by Kinomescan method relative to control,Kinomescan method,KINOMEScan assay,BAO_0003011
2066315,B,Inhibition of wild-type human partial length ULK1 (M1 to T309 residues) expressed in mammalian expression system assessed as residual activity at 1 uM by Kinomescan method relative to control,Kinomescan method,KINOMEScan assay,BAO_0003011
1703701,B,Inhibition of wild-type human partial length PKCH (S324 to P683 residues) expressed in bacterial expression system assessed as residual activity at 50 nM by Kinomescan method relative to control,Kinomescan method,KINOMEScan assay,BAO_0003011
1903361,B,Inhibition of wild-type human partial length SYK (D354 to N635 residues) expressed in bacterial expression system at 1 uM by Kinomescan method relative to control,Kinomescan method,KINOMEScan assay,BAO_0003011
1693188,B,Inhibition of wild-type human partial length NDR2 (N34 to E447 residues) expressed in Escherichia coli BL21 assessed as residual activity at 1000 nM after 30 mins by Kinomescan method relative to control,Kinomescan method,KINOMEScan assay,BAO_0003011
1808537,B,Binding affinity to wild-type human partial length MARK1 (Q30 to T341 residues) expressed in bacterial expression system assessed as residual binding level at 10 uM by Kinomescan method relative to control,Kinomescan method,KINOMEScan assay,BAO_0003011
1864995,B,Inhibition of wild-type human partial length SIK (M1 to Y304 residues) expressed in bacterial expression system assessed as residual activity at 10 uM by Kinomescan method relative to control,Kinomescan method,KINOMEScan assay,BAO_0003011
1833493,B,Binding affinity to wild-type human full length MKNK1 (M1 to L424 residues) expressed in mammalian expression system assessed as residual binding level at 1 uM by Kinomescan method relative to control,Kinomescan method,KINOMEScan assay,BAO_0003011
1675304,B,Inhibition of wild-type human partial length YSK4 (T1019 to H1328 residues) expressed in mammalian expression system assessed as residual activity at 1 uM by Kinomescan method relative to control,Kinomescan method,KINOMEScan assay,BAO_0003011
1773600,B,Binding affinity to wild-type human partial length BLK (G211 to L503 residues) expressed in bacterial expression system assessed as residual binding level at 1 uM by Kinomescan method relative to control,Kinomescan method,KINOMEScan assay,BAO_0003011
2154276,B,Inhibition of human recombinant Mnk2 assessed as reduction in substrate phosphorylation at 50 to 500 nM using ATP and CREBtide (CKRREILSRRPSYRK) as substrate incubated for 90 min by LANCE detection method,LANCE detection method,,
1829280,B,Inhibition of IDH1 R132C mutant in human HT1080 cells assessed as inhibition of 2HG production after 48 hrs by LC-MS/MS analysis,LC-MS/MS analysis,mass spectrometry,BAO_0000055
1849706,B,Inhibition of PHGDH-mediated serine synthesis in human Carney cells in serine free medium at 40 uM preincubated for 1 hr followed by 13C6 labelled glucose addition and measured after 2 hrs by LC/MS analysis based 13C6-Glucose tracing assay relative control,LC/MS analysis,mass spectrometry,BAO_0000055
2073738,B,Negative allosteric modulator activity at human PDE5A1 (535-860 residues) expressed in Escherichia coli BL21 assessed as Kcat for cGMP at 50 nM incubated for 15 mins using [3H]-cGMP as substrate by liquid scintillation counting method (Rvb = 2.53 +/- 0.24 /s),liquid scintillation counting method,scintillation counting,BAO_0000405
1870590,B,Mixed-type inhibition of human GAT1 expressed in COS cells assessed as reduction in [2H6]GABA uptake by measuring [2H6]GABA Km(app) at 300 nM preincubated for 25 mins followed by [3H]GABA addition and measured after 4 mins by liquid scintillation counting method (Rvb = 12 +/- 1.2 uM),liquid scintillation counting method,scintillation counting,BAO_0000405
1930475,B,Agonist activity at human LXRalpha transfected in HepG2 at 10 uM by luciferase reporter assay,luciferase reporter assay,luciferase reporter gene assay,BAO_0002661
1991216,B,Antagonist activity at human VDR transfected in HEK293T cells measured after 24 hrs by luciferase reporter gene assay,luciferase reporter gene assay,luciferase reporter gene assay,BAO_0002661
2185625,B,Inhibition of N-terminal 6XHis-SUMO2 fused full length human cGAS (1 to 522 residues) expressed in human THP-1 cells transfected with HT-DNA incubated for 20 mins in presence of ATP by luminescence based analysis,luminescence based analysis,luminescence method,BAO_0000045
1565356,B,Inhibition of human recombinant PTP-1B using IR5 insulin receptor residues as substrate at 100 uM after 30 mins by malachite green assay,malachite green assay,malachite green,BAO_0002580
1971164,B,Binding affinity to IDH1 R132C mutant (unknown origin) by mass spectrometry,mass spectrometry,mass spectrometry,BAO_0000055
1708265,B,Inhibition of CaMK2g in human SKCO1 cells at 1 uM after 4 hrs using biotin labeled TSTQEYAAKIINTK probe by mass-spectrometric analysis relative to control,mass-spectrometric analysis,mass spectrometry,BAO_0000055
2081184,B,Inhibition of CAH9 in human UFH-001 cells under normoxic condition by membrane inlet for mass spectrometry,membrane inlet for mass spectrometry,mass spectrometry,BAO_0000055
1729642,B,Inhibition of recombinant human DGAT1 expressed in baculovirus infected Sf9 insect microsomal membranes using C10-DAG and [3H]-labelled decanoyl-CoA as substrates pretreated for 30 mins in presence of C10-DAG followed by [3H]-labelled decanoyl-CoA addition measured after 60 mins by microbeta counting method,microbeta counting method,scintillation counting,BAO_0000405
1809282,B,Displacement of [3H]-Nisoxetine from human recombinant NET receptor expressed in stable HEK cells after 90 mins by microbeta scintillation counting method,microbeta scintillation counting method,scintillation counting,BAO_0000405
1809315,B,Displacement of [3H]-Win35428 from human recombinant DAT receptor expressed in stable HEK cells at 10 uM after 90 mins by microbeta scintillation counting method relative to control,microbeta scintillation counting method,scintillation counting,BAO_0000405
1904958,B,Displacement of [3H]ZM241385 from recombinant human A2A receptor incubated for 90 mins under dark condition by microbeta scintillation method,microbeta scintillation method,scintillation counting,BAO_0000405
1785169,B,Inhibition of INSR (unknown origin) at 30 uM using peptide as substrate in presence of ATP and MgCl2 by mobility shift assay relative to control,mobility shift assay,mobility shift assessment method,BAO_0003033
1625341,B,Inhibition of human ABCB1 expressed in KBV1 cells assessed as potentiation of doxorubicin-induced cytotoxicity by measuring doxorubicin IC50 at 200 nM after 72 hrs by MTT assay (Rvb = 5.07 +/- 0.19 uM),MTT assay,MTT reduction assay,BAO_0002457
2069435,B,"Displacement of (1-(2-aminoethyl)-3,5-dimethyl-1H-pyrazol-4-yl)(4-((1-neopentyl-1H-benzo[d]imidazol-2-yl)methyl)piperazin-1-yl)methanone from FNTA in vorinostat-stimulated human Jurkat 2C4 cells infected with latent HIV-1 by pull-down experiment based competitive binding assay",pull-down experiment based competitive binding assay,affinity selection,BAO_0002501
1801095,B,Inhibition of basal ATPase activity of N-terminal His6-tagged human Eg5 motor domain (1 to 368 residues) expressed in Escherichia coli BL21 (DE3) by pyruvate kinase-lactate dehydrogenase coupled assay,pyruvate kinase-lactate dehydrogenase coupled assay,coupled enzyme activity measurement method,BAO_0000142
1894049,B,Inhibition of human topoisomerase-2alpha assessed as rate of ATP hydrolysis at 50 uM using pBR322 as substrate measured up to 30 mins in presence of 0.05 mM ATP by pyruvate kinase/lactate dehydrogenase enzyme coupled assay (Rvb = 0.238 to 0.559 microM/min),pyruvate kinase/lactate dehydrogenase enzyme coupled assay,coupled enzyme activity measurement method,BAO_0000142
1745604,B,Inhibition of human Nav1.7 expressed in CHO-K1 cells at -120 mV holding potential incubated over 5 mins measured at 15 secs interval by Qpatch clamp assay,Qpatch clamp assay,patch clamp,BAO_0000062
1585034,B,Binding affinity to MDM2 in human U87MG cells assessed as inhibition of MDM2/p53 protein interaction after 10 mins by quantitative sandwich immuno assay,quantitative sandwich immuno assay,sandwich ELISA,BAO_0002421
1742172,B,Inhibition of human MKK1 assessed as enzyme residual activity at 100 nM by radiometric filter binding assay relative to control,radiometric filter binding assay,filter assay,BAO_0000401
2196852,B,Inhibition of TRKB (unknown origin) in presence of [gamma33P]ATP by radiometric HotSpot assay,radiometric HotSpot assay,,
1877750,B,Inhibition of human recombinant ASK1 (649 to 946 residues) using myelin as substrate incubated for 40 mins in presence of [gamma-33ATP] by radiometric scintillation counting analysis,radiometric scintillation counting analysis,scintillation counting,BAO_0000405
1878057,B,Inhibition of recombinant full-length human STK33 using myelin basic protein as substrate incubated for 40 mins in presence of [gamma33P]ATP by radiometric scintillation counting analysis,radiometric scintillation counting analysis,scintillation counting,BAO_0000405
1724006,B,Inhibition of human SMS2 expressed in HEK293T cells at 100 uM using C2-ceramide as substrate preincubated for 60 mins followed by substrate addition measured after 30 mins by RapidFire/mass spectrometry assay relative to control,RapidFire/mass spectrometry assay,RapidFire Mass Spec,BAO_0002577
1707818,B,Inhibition of HuR-ERBB2 mRNA interaction in human MCF7 cells at 5 uM after 6 hrs by RNA immunoprecipitation assay,RNA immunoprecipitation assay,immunoassay,BAO_0000129
2115142,B,Inhibition of CBP in human MOLM-13 cells assessed as reduction in H3K27Ac level at 3 uM incubated for 2 hrs by RT-PCR analysis,RT-PCR analysis,reverse transcription PCR,BAO_0002089
1881441,B,Inhibition of GGPPS in human RPMI8226 cells assessed as induction of ER-stress induced XBP1 mRNA splicing at 100 to 1000 nM by RT-PCR analysis,RT-PCR analysis,reverse transcription PCR,BAO_0002089
2085469,B,Inhibition of recombinant human CK1delta (1 to 294 residues) assessed as residual activity at 10 uM using KRRRALS(p)VASLPGL as substrate incubated for 40 mins in presence of [gamma-33ATP] by scintillation counting based radiometry assay relative to control,scintillation counting,scintillation counting,BAO_0000405
2017553,B,Displacement of [125I]+/-DOI from human recombinant 5-HT2B receptor at 10 uM after 60 mins by scintillation counting analysis relative to control,scintillation counting analysis,scintillation counting,BAO_0000405
1673543,B,Displacement of [3H]-CP55950 from human CB1 receptor expressed in CHO cell membranes after 3 hrs by scintillation counting method,scintillation counting method,scintillation counting,BAO_0000405
1676262,B,Inhibition of human PDE4D catalytic domain using [3H]-cAMP as substrate after 30 mins by scintillation counting method,scintillation counting method,scintillation counting,BAO_0000405
1905613,B,Inhibition of recombinant human cRaf (306 to end residues) at 1 uM using unactive MEK1 as substrate incubated for 40 mins in presence of [gamma-33P]-ATP by scintillation counting method relative to control,scintillation counting method,scintillation counting,BAO_0000405
1876338,B,"Inhibition of recombinant human cKit (544 to end residues) at 1 uM using using Poly(Glu,Tyr) 4:1 as substrate measured after 40 mins in presence of [gamma33P]ATP by scintillation counting method relative to control",scintillation counting method,scintillation counting,BAO_0000405
1698355,B,Displacement of [125I]SDF-1alpha from CXCR4 (unknown origin) expressed in HEK293 cells after 1 hr by scintillation counting method,scintillation counting method,scintillation counting,BAO_0000405
1876505,B,Inhibition of recombinant human IRAK1 (194 to end residues) at 1 uM using myelin basic protein as substrate measured after 40 mins in presence of [gamma33P]ATP by scintillation counting method relative to control,scintillation counting method,scintillation counting,BAO_0000405
2118948,B,Inhibition of human TLR7 in HEK-Blue hTLR7 cells assessed as reduction in gardiquimod-activated NF-KappaB by SEAP reporter assay,SEAP reporter assay,reporter gene assay,BAO_0003006
1674489,B,Agonist activity at human NOD2 expressed in HEK-Blue cells assessed as induction of NF-kB transcriptional activity at 20 uM after 18 hrs by SEAP reporter gene assay,SEAP reporter gene assay,reporter gene assay,BAO_0003006
2063770,B,Inhibition of His-tagged PTPmu (unknown origin) expressed in Escherichia coli BL21 cells using para-nitrophenyl phosphate as substrate incubated for 5 to 10 mins by microplate reader based spectrophotometric analysis,spectrophotometric analysis,spectrophotometry method,BAO_0000049
1558657,B,Inhibition of human recombinant NQO2 using DCPIPas substrate and NRH as cofactor measured for 1 min by spectrophotometry in the absence of BSA,spectrophotometry,spectrophotometry method,BAO_0000049
2208145,B,Binding affinity to S1PR2 (unknown origin) by SPR assay,SPR assay,surface plasmon resonance,BAO_0000054
1658550,B,Binding affinity to PPARgamma (unknown origin) assessed as kinetic dissociation constant by SPR assay,SPR assay,surface plasmon resonance,BAO_0000054
2081167,B,Inhibition of human CAH14 expressed in Escherichia coli BL21 (DE3) by stopped flow CO2 hydration assay,stopped flow CO2 hydration assay,,
2196705,B,Inhibition of amyloid beta (1 to 42) (unknown origin) aggregation at 75 uM incubated for 1 hr by thioflavin-T fluorescence method,thioflavin-T fluorescence method,fluorescence method,BAO_0000046
1691198,B,Inhibition of human GSK3beta using YRRAAVPPSPSLSRHSSPHQS(PO4)EDEEENH as substrate after 60 mins in presence of [gamma32P]ATP by TopCount method,TopCount method,scintillation counting,BAO_0000405
2221491,B,Inhibition of PKN2 (unknown origin) by TR-FRET-based tracer displacement assay dependent Cheng-Prusoff equation analysis,TR-FRET-based tracer displacement assay,time resolved fluorescence resonance energy transfer,BAO_0000004
1734342,B,Negative allosteric modulation of human GluN2A receptor expressed in Xenopus laevis oocytes assessed as inhibition of glutamate/glycine-induced channel current at 3 uM after 10 to 15 mins by two electrode voltage clamp based electrophysiology assay,two electrode voltage clamp based electrophysiology assay,patch clamp,BAO_0000062
2076539,B,Induction of eNOS phosphorylation in FFA-induced oxidatively stress human HepG2 cells by Western blot analysis relative to control,Western blot analysis,western blot,BAO_0002424
2091862,B,Inhibition of BTK in human Ramos cells assessed as reduction in anti-human IgM F(ab)2-induced BTK phosphorylation at Tyr551 residue preincubated for 10 mins followed by stimulated with antihuman IgM F(ab)2 incubated for 60 mins by Western blot analysis,Western blot analysis,western blot,BAO_0002424
1991397,B,Inhibition of KRAS in human MDA-MB-231 cells assessed as reduction in phosphorylation of RAF measured after 24 hrs by Western blot analysis,Western blot analysis,western blot,BAO_0002424
2058599,B,Inhibition of ALK in human NCI-H3122 cells assessed as downregulation of AKT expression levels at 10 to 500 nM incubated for 24 hrs by western blot analysis,western blot analysis,western blot,BAO_0002424
2087246,B,Activation of NAE1-mediated neddylation in human MGC-803 cells assessed as increase in Nedd8-Ubcl2 adduct formation at 50 to 150 nmol/L measured after 24 hrs by Western blot analysis,Western blot analysis,western blot,BAO_0002424
2088829,B,Inhibition of EGF-induced phosphorylation of EGFR L858R/T790M double mutant in human H1975 cells incubated for 2 hrs followed by EGF stimulation for 10 mins by western blot analysis,western blot analysis,western blot,BAO_0002424
1696265,B,Inhibition of mTOR binding to DEPTOR in human RPMI8226 cells assessed as increase in mTORC1-associated p70 phosphorylation after 6 hrs by Western blot analysis relative to control,Western blot analysis,western blot,BAO_0002424
1730073,B,Inhibition of GAK in human HuH7 cells assessed as reduction in AP2M1 phosphorylation levels up to 10 uM after 4 hrs in presence of PP2A inhibitor calyculin A by Western blot analysis,Western blot analysis,western blot,BAO_0002424
2087582,B,Inhibition of STAT5 phosphorylation in imatinib-resistant human K562 cells in presence of imatinib at 10 uM measured after 6 hrs by Western blot assay,Western blot assay,western blot,BAO_0002424
1648344,B,Inhibition of PTP1B in human HuH7 cells assessed as reduction in insulin-stimulated Akt phosphorylation at 5 uM preincubated for 2 hrs followed by insulin stimulation for 5 mins by Western blot method,Western blot method,western blot,BAO_0002424
2109375,B,Inhibition of MALT1 in human Jurkat cells assessed as decrease in CYLD substrate cleavage by Western blotting analysis,Western blotting analysis,western blot,BAO_0002424
1814455,B,Inhibition of recombinant His-tagged human FGFR1 (308 to 731 resides) expressed in baculovirus expression system at 0.5 uM using tyr 04 as substrate in presence of ATP at Km concentration after 1 hr by Z'-LYTE assay relative to control,Z'-LYTE assay,,
1795953,B,Inhibition of recombinant human full length His-tagged Aurora A expressed in baculovirus expression system using peptide substrate after 1 hr by Z'-Lyte assay,Z'-Lyte assay,,
2013398,B,Inhibition of recombinant human His-tagged CSF1R (538 to 910 residues) expressed in baculovirus expression system using Tyr 01 as substrate at 0.1 uM incubated for 60 mins by Z'-Lyte assay relative to control,Z'-Lyte assay,,
2244768,B,Inhibition of MAPK8 (unknown origin) at 50 nM by Z'LYTE screening method relative to control,Z'LYTE screening method,,
1546446,B,Inhibition of human c-Kit using poly[Glu:Tyr] (4:1) as substrate,,,
1575333,B,Inhibition of GARFTase (unknown origin),,,
2187796,B,Binding affinity to N-terminal P62 (1 to 335 residues) in human HCT-116 cells lysates,,,
1794453,B,Inhibition of recombinant human N-terminal His6-tagged full length FYN expressed in baculovirus infected Sf21 insect cells at 1 uM relative to control,,,
2072747,B,Binding affinity to CLK4 (unknown origin),,,
1544235,B,Inhibition of Rsk3 (unknown origin) at 1 uM,,,
1554559,B,Binding affinity to recombinant 5-HT1B receptor (unknown origin) after 1.5 hrs by radioligand displacement assay,,,
1711487,B,Inhibition of recombinant His-tagged human FGFR1 cytoplasmic domain expressed in baculovirus expression system at 10 uM in presence of ATP relative to control,,,
2123529,B,Reversible inhibition of recombinant full length LSD1 (unknown origin) transfected in Escherichia coli BL21 (DE) assessed as enzyme recovery activity by jump dilution assay relative to control,jump dilution assay,dilution method,BAO_0002418
1740028,B,Inhibition of wild-type BRAF (unknown origin) at 1 uM relative to control,,,
1755636,B,Inhibition of human TRPM8,,,
1842485,B,Inhibition of EGFR T790M mutant (unknown origin),,,
1857915,B,Activity at human OX1 receptor up to 10 uM,,,
1892894,B,Antagonist activity at D4 receptor (unknown origin),,,
1898332,B,Inhibition of PDK2 in human MG63 cells assessed as reduction in lactate formation at 2 to 10 uM incubated for 4 hrs,,,
1928208,B,Inhibition of EGFR (unknown origin) at 20 nM relative to control,,,
2065931,B,Inhibition of human ALK3 assessed as residual activity using casein as substrate at 1 uM by [gamma-33P]-ATP assay relative to control,,,
1571983,B,Inhibition of HDAC9 catalytic domain (unknown origin) using Boc-Lys(TFA)-AMC as substrate,,,
1629935,B,Reversible inhibition of recombinant human C-terminal His6-tagged IDO2 (14-420 residues) expressed in Escherichia coli BL21(DE3) assessed as reduction in L-kynurenine formation using L-tryptophan as substrate after 30 mins,,,
1661450,B,Inhibition of TNFalpha-stimulated RIPK2 in human U937 cells in presence of 5 uM ATP,,,
2112908,B,Inhibition of BRD4-BD1 (unknown origin) preincubated for 15 mins followed by substrate addition and measured after 1 hr,,,
2201141,B,Binding affinity to Bcl-XL (unknown origin),,,
1760563,B,Inhibition of recombinant human N-terminal His-tagged BAZ2B (1 to 913 residues) expressed in Escherichia coli at 10 uM relative to control,,,
2086338,B,Inhibition of His-tagged full length human CHK1 expressed in baculovirus expression system at 1 uM by Selectscreen kinase assay,,,
1562687,B,Inhibition of N-terminal His6-tagged recombinant human HCK expressed in baculovirus infected insect Sf9 cells assessed as remaining activity at 1 uM relative to control,,,
1587012,B,Inhibition of CDK8 (unknown origin),,,
1718296,B,Inhibition of AKT (unknown origin) assessed as residual activity at 10 uM relative to control,,,
2121636,B,Inhibition of HDAC10 (unknown origin) at 0.5 uM relative to control,,,
2204318,B,Inhibition of Abl T315I mutant (unknown origin) at 1 uM relative to control,,,
2251008,B,Negative allosteric modulation activity against human ATX using FS-3 as substrate preincubated for 45 mins followed by substrate addition and measured every 30 mins by multi-mode microplate reader,,,
1743774,B,Inhibition of recombinant human full length N-terminal GST-tagged MST1 expressed in baculovirus infected Sf9 cells assessed as change in enzyme activity at 1 uM in presence of 1 uM ATP relative to control,,,
1787146,B,Binding affinity to dopamine D3 receptor (unknown origin) assessed as inhibition of radioligand binding by radioligand competition binding assay,,,
1911716,B,Inhibition of recombinant human GST-tagged CK2alpha at 10 uM in presence of ATP by radiometric kinase assay relative to control,,,
1683894,B,Inhibition of MAP2K3 Lysine 2 labelling site (unknown origin) at 10 uM,,,
1710591,B,Inhibition of DYRK3 (unknown origin) at 0.19 uM relative to control,,,
2150702,B,Inhibition of TrkC (unknown origin) by radiometric assay,,,
1865723,B,Inhibition of PKA (unknown origin) at 1 uM relative to control,,,
1985872,B,Inhibition of MYST2 (unknown origin),,,
2049841,B,Inhibition of GST-tagged recombinant PDGFRbeta (unknown origin) expressed in baculovirus expression system incubated for 15-45 mins in presence of [gamma32P]-ATP by radiometric assay,,,
2069991,B,Inhibition of human HIPK2 assessed as remaining enzyme activity at 1 uM,,,
2070437,B,Inhibition of MEK5 (unknown origin),,,
1547676,B,Inhibition of human recombinant MMP10 expressed in Escherichia coli using (5-FAM/QXLTM) FRET peptide as substrate,,,
2118419,B,Inhibition of human CREBBP (A1040 to G1161 residues) at 10 uM by DiscoverX assay relative to control,,,
2254758,B,Binding affinity to 5-HT5A receptor (unknown origin) at 10000 nM by radioligand displacement assay relative to control,,,
2261490,B,Inhibition of ABCG2 (unknown origin) overexpressing in dog MDCK-II-BCRP cells,,,
1747422,B,Binding affinity to recombinant full length human N-terminal GST-tagged Syk-KD (356 to 635 residues) cytoplasmic domain expressed in baculovirus infected Sf9 insect cells using poly EY 4:1 as substrate,,,
1898090,B,Inhibition of human activated protein C,,,
1576452,B,Inhibition of PRMT6 (unknown origin) at 10 uM relative to control,,,
1583673,B,Inhibition of PI3K delta (unknown origin),,,
1706120,B,Inhibition of NuaK1 (unknown origin) at 0.45 uM relative to control,,,
1737901,B,Inhibition of EZH2 (unknown origin) at 33 uM relative to control,,,
1769009,B,Inhibition of Xanthine oxidase (unknown origin) using xanthine as substrate preincubated for 1 to 5 mins followed by substrate addition,,,
1829129,B,Inhibition of recombinant human full-length N-terminal His-tagged Tdp1 expressed in Escherichia coli BL21,,,
1855714,B,Inhibition of human TLR7 expressed in mouse RAW264.7 cells assessed as resiquimod-induced NO production at > 5 uM incubated for 18 to 24 hrs,,,
2062261,B,Inhibition of N-terminal GST-tagged human FLT4 (800 to end residues) expressed in baculovirus infected Sf21 cells assessed as residual activity at 10 uM relative to control,,,
1583101,B,Inhibition of full length recombinant human GST-tagged PRKX expressed in baculovirus expression system at 1 uM relative to control,,,
2173021,B,Inhibition of DLK (unknown origin) at 1 uM,,,
2193286,B,Noncompetitive inhibition of GOT1 (unknown origin) using aspartic acid and alpha-ketoglutaric acid as substrate incubated in presence of pyridoxal 5'-phosphate,,,
2231389,B,Inhibition of BTK (unknown origin) at 1.0 uM relative to control,,,
1778345,B,Inhibition of CLK3 (unknown origin),,,
1848946,B,Inhibition of cSRC (unknown origin),,,
2093877,B,Inhibition of c-SRC (unknown origin),,,